
==== Front
Front Cell Neurosci
Front Cell Neurosci
Front. Cell. Neurosci.
Frontiers in Cellular Neuroscience
1662-5102
Frontiers Media S.A.

10.3389/fncel.2021.670346
Neuroscience
Review
Regulation of Glutamate, GABA and Dopamine Transporter Uptake, Surface Mobility and Expression
Ryan Renae M. 1

Ingram Susan L. 2

Scimemi Annalisa 3*

1School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia
2Department of Neurological Surgery, Oregon Health & Science University, Portland, OR, United States
3Department of Biology, SUNY Albany, Albany, NY, United States
Edited by: Fiorenzo Conti, Marche Polytechnic University, Italy

Reviewed by: Janosch P. Heller, Dublin City University, Ireland; Michael B. Robinson, Children’s Hospital of Philadelphia Research Institute, United States

*Correspondence: Annalisa Scimemi, scimemia@gmail.com; ascimemi@albany.edu
This article was submitted to Cellular Neurophysiology, a section of the journal Frontiers in Cellular Neuroscience

13 4 2021
2021
15 67034621 2 2021
15 3 2021
Copyright © 2021 Ryan, Ingram and Scimemi.
2021
Ryan, Ingram and Scimemi
https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Neurotransmitter transporters limit spillover between synapses and maintain the extracellular neurotransmitter concentration at low yet physiologically meaningful levels. They also exert a key role in providing precursors for neurotransmitter biosynthesis. In many cases, neurons and astrocytes contain a large intracellular pool of transporters that can be redistributed and stabilized in the plasma membrane following activation of different signaling pathways. This means that the uptake capacity of the brain neuropil for different neurotransmitters can be dynamically regulated over the course of minutes, as an indirect consequence of changes in neuronal activity, blood flow, cell-to-cell interactions, etc. Here we discuss recent advances in the mechanisms that control the cell membrane trafficking and biophysical properties of transporters for the excitatory, inhibitory and modulatory neurotransmitters glutamate, GABA, and dopamine.

glutamate
GABA
dopamine
transporter
uptake
surface mobility
==== Body
Glutamate Transporters

In addition to being one of the most abundant amino acids and the main excitatory neurotransmitter in the brain, glutamate controls synapse formation, and maturation, acts as an energy substrate for oxidative metabolism, contributes to the antioxidant properties of glutathione, and can be used as a building block for non-ribosomal peptide synthesis and as the precursor for the biosynthesis of the inhibitory neurotransmitter GABA (Sieber and Marahiel, 2005; Brosnan and Brosnan, 2013; Martinez-Lozada et al., 2016; Walker and van der Donk, 2016). In addition, in the developing brain, glutamate guides cell proliferation, migration, differentiation, and survival of neural progenitor cells (Jansson et al., 2013). Because of the plethora of effects that glutamate can exert, its lifetime in the extracellular space needs to be finely controlled through the activity of a family of Na+- and K+-dependent secondary active transporters. Geneticists, structural biologists, physiologists and clinicians all have their preferred nomenclature to refer to the five known glutamate transporters subtypes, summarized as follows: (i) Slc1a1/SLC1A1/EAAC1/EAAT3; (ii) Slc1a2/SLC1A2/GLT1/EAAT2; (iii) Slc1a3/SLC1A3/GLAST/EAAT1; (iv) Slc1a6/SLC1A6/EAAT4; (v) Slc1a7/SLC1A7/EAAT5. The use of each terminology is physiologically meaningful, as it refers to the genes encoding each transporter in rodents (Slc1a1, Slc1a2, Slc1a3, Slc1a6, Slc1a7) and in humans (SLC1A1, SLC1A2, SLC1A3, SLC1A6, SLC1A7), or the protein product in rodents (EAAC1, GLT1, GLAST, EAAT4-5) and humans (EAAT1-5). For simplicity, in this review, we refer to them as EAAT1-5. Different subtypes of glutamate transporters are differentially expressed in neuronal and glial cells (Danbolt, 2001). Accordingly, the glutamate transporters EAAT1-2 are mostly expressed in astrocytes, whereas EAAT3-5 are mostly expressed in neurons. Two of the neuronal transporters are predominantly expressed in the cerebellum (EAAT4) or retina (EAAT5), with a low yet experimentally measurable concentration in the forebrain (Dehnes et al., 1998; Danbolt, 2001). The others (i.e., EAAT1, EAAT2, and EAAT3) are expressed broadly throughout the brain, at varying levels.

Structural information of the glutamate transporters comes from prokaryote homologs such as GltPh and GltTk which share ∼35 amino acid identity with human EAAT2 (Yernool et al., 2004; Boudker et al., 2007; Reyes et al., 2009; Verdon and Boudker, 2012; Guskov et al., 2016; Scopelliti et al., 2018) and more recent crystal and cryo-EM structures of human transporters including EAAT1, EAAT3, and ASCT2 (Canul-Tec et al., 2017; Garaeva et al., 2018; Garaeva et al., 2019; Yu et al., 2019; Wang and Boudker, 2020) (Figure 1). All members of this family appear to assemble as trimers, with each monomer capable of transporting substrate and coupled ions, generating stoichiometric and non-stoichiometric currents, independently of the two other monomers (Grewer et al., 2005; Koch et al., 2007; Leary et al., 2007). The transporters are composed of a “transport domain” which binds and transports substrate and coupled ions, and a “scaffold domain” that forms inter-protomer contacts and interacts with the lipid membrane (Boudker et al., 2007; Reyes et al., 2009). GltPh transports aspartate together with three Na+ ions into the cytoplasm using a twisting elevator mechanism (Reyes et al., 2009; Ryan and Vandenberg, 2016) and generates a stoichiometrically uncoupled Cl– conductance (Boudker et al., 2007; Ryan and Mindell, 2007; Reyes et al., 2009).

FIGURE 1 Crystal structure of GltPh, a bacterial homolog of glutamate transporters (PDB: 2NWX). (A) Side view of the glutamate transporter trimer parallel to the membrane, using a ribbon (top) and a surface representation sliced through the center of the transporter basin (bottom). (B) As in A, viewed from the extracellular side of the membrane. Aspartate (magenta) and sodium ions (blue) are represented as spheres. (C) Summary of the main feature of the stoichiometric and non-stoichiometric current mediated by glutamate transporters in prokaryotes and eukaryotes, respectively. Image generated using The PyMOL Molecular Graphics System (Version 2.3.2; Schrödinger, 2010).

In contrast to prokaryotes, for all eukaryotic transporters, glutamate uptake is driven by the electrochemical gradient for Na+ and H+ ions, and the rate limiting step is the counter-transport of one K+ ion across the membrane (Zerangue and Kavanaugh, 1996). The stoichiometry of the transport process is the inward movement of 1 glutamate (which carries a negative charge): 3 Na+: 1 H+, followed by the counter-transport of 1 K+, leading to the net influx of two positive charges per transport cycle (Zerangue and Kavanaugh, 1996; Levy et al., 1998). In addition, these transporters mediate a glutamate-dependent anion flux, which under physiological conditions is carried by Cl– ions (Picaud et al., 1995; Wadiche et al., 1995b; Eliasof and Jahr, 1996). The chloride channel forms at the interface of the transport and scaffold domains during the transport cycle (Ryan et al., 2004; Cater et al., 2014, 2016; Cheng et al., 2017; Kolen et al., 2020; Chen et al., 2021) and the direction of this flux is determined by the driving force for chloride (i.e., the difference between membrane potential and reversal potential for chloride). The function of the chloride current remains incompletely understood but it has been suggested that it might serve to counterbalance the influx of positive charges due to glutamate transport and prevent cell depolarization (Grewer and Rauen, 2005). This hypothesis would only hold true in the presence of a positive driving force for chloride, causing an inward movement of chloride into the cell. This occurs when the reversal potential for chloride is more hyperpolarized than the membrane potential. This condition, however, is not fulfilled in developing neurons. Here, the reversal potential for chloride is more depolarized than in mature neurons, due to a delayed expression of the potassium chloride co-transporter KCC2, and a consequently higher intracellular chloride concentration in developing compared to mature neurons (Rivera et al., 1999). Other physiological roles for the chloride conductance have been demonstrated with EAAT5 in the retina, where it regulates cell activity and neurotransmitter release (Picaud et al., 1995; Veruki et al., 2006) and in cerebellar astrocytes, where the chloride currents of EAAT1/2 affects the resting intracellular chloride concentration (Sonders and Amara, 1996; Untiet et al., 2017).

Similarities and Distinctive Biophysical Features of Different Glutamate Transporter Subtypes

The general mechanisms of substrate transport, identified through studies of uptake of radiolabeled substrates or voltage-clamp recordings of transporter currents under steady-state conditions, are roughly similar among different glutamate transporter types. For all of them, the transport efficiency is in the order of ∼50%, which means that − perhaps surprisingly − these molecules translocate into the cell cytoplasm only 50% of all glutamate molecules they bind (Tzingounis and Wadiche, 2007). The remaining 50% of glutamate molecules that unbind from the transporters are released back in the extracellular space, and ultimately bind to nearby glutamate receptors, neuronal or glial transporters. This low transport efficiency can lead to an apparently paradoxical prolongation of glutamate lifetime in the extracellular space (Scimemi et al., 2009). Since the rates of glutamate binding to receptors and transporters are relatively similar, the likelihood that a glutamate molecule unbound from a transporter will eventually bind to a receptor or another transporter depends on the relative abundance of receptors compared to that of transporters. Typically, the surface density of expression of transporters in glial membranes is four orders of magnitude higher than that of glutamate receptors in extra-synaptic neuronal membrane (Lehre and Danbolt, 1998). For this reason, the most likely ultimate fate of glutamate molecules unbound from transporters is to be bound again by other transporter molecules (Leary et al., 2011).

Non-rate-limiting partial reaction steps, obtained by perturbing the steady-state and by subsequently following the kinetics of the relaxation to a new steady-state (i.e., the pre-steady-state kinetics), are similar for EAAT1-3 (Grewer and Rauen, 2005). However, the pre-steady-state kinetics and steady-state turnover rats are significantly slower for EAAT4 (Mim et al., 2005). There are also notable differences in the steady state affinity of different transporter types (km EAAT1: 48 ± 10 μM; EAAT2: 97 ± 4 μM; EAAT3: 62 ± 8 μM; EAAT4: 0.6 μM; Wadiche and Kavanaugh, 1998; Grewer et al., 2000; Bergles et al., 2002), and in the ratio of substrate transport versus anion permeation (Arriza et al., 1994; Seal and Amara, 1999; Mim et al., 2005; Torres-Salazar and Fahlke, 2007). Interestingly, and in contrast to EAAT1-3, the apparent affinity for glutamate is voltage dependent for EAAT4 and increases with negative voltages, suggesting higher glutamate buffering capacity for EAAT4 than other glutamate transporters (Mim et al., 2005). The fact that EAAT4 has a 10-fold higher affinity for glutamate but a 10-fold slower translocation rate than other transporters has led to hypothesize that the main functional role of EAAT4 is accounted for by its ability to generate a stoichiometrically uncoupled anion current (Fairman et al., 1995; Lin et al., 1998). Others have suggested that these biophysical properties would allow EAAT4 to clear glutamate away from synapses, where its concentration is lower than at the outer boundary of the synaptic cleft (Mim et al., 2005). Consistent with this hypothesis, one of the most prominent roles of EAAT4 is to limit metabotropic glutamate receptor activation in cerebellar Purkinje cells, in sub-cellular domains where the density of expression of these receptors and EAAT4 are both high (Wadiche and Jahr, 2005).

Glutamate transport via EAAT4 has a unique voltage-dependence. Its maximum transport activity is detected at –20 mV < Vm < 0 mV and the transporter inactivates at more negative membrane potentials (Mim et al., 2005). Membrane hyperpolarization promotes glutamate transport via other glutamate transporters, which have reversal potentials of 9.3 ± 0.7 mV (EAAT1), >80 mV (EAAT2) and 38.0 ± 2.7 mV (EAAT3) (Arriza et al., 1994). At hyperpolarized potentials, not only transport, but also the anion conductance of EAAT4 is inhibited (Mim et al., 2005). This means that at membrane potentials close to the resting potential of neurons, glutamate is bound strongly to all transporters, but its transport via EAAT4 is inhibited (Mim et al., 2005).

There are differences in the sodium requirement for activation of the anion conductance between neuronal and glial glutamate transporters (Wadiche et al., 1995a; Grewer et al., 2000, 2001; Otis and Kavanaugh, 2000). For EAAT3, the anion conductance can be activated by glutamate and Na+ ions from both sides of the membrane (Watzke and Grewer, 2001). The activation of the anion conductance by sodium alone has only been demonstrated for EAAT3-4, while EAAT1-2 mediate glutamate- and sodium-independent anion conducting states (Divito et al., 2017). For EAAT4-5, the anion conductance is particularly large compared to their glutamate transport capacity (Sonders and Amara, 1996; Seal et al., 2001). Consequently, transport currents generated by EAAT1-3 are easily measured experimentally using heterologous expression systems, whereas those mediated by EAAT4-5 are relatively small (Wadiche et al., 1995a; Grewer et al., 2001; Mitrovic et al., 2001; Watzke et al., 2001).

The existence of functional differences in the properties of glutamate transporter subtypes indicates that the function of these molecules is much more complex than previously thought, and that an evaluation of the physiological implications of glutamate transporters cannot bypass an understanding of the biophysical properties of these molecules in their native environments.

The Surface Mobility and Cellular Distribution of EAAT2

Out of all glutamate transporter types, EAAT2 has the highest density of expression in the adult brain, and is responsible for the largest proportion of glutamate transport (Minelli et al., 2001). In astrocytes, 70–75% of all EAAT2 is expressed on the plasma membrane (Michaluk et al., 2020). In the hippocampus, cerebellum and neocortex, EAAT2 is expressed mostly in astrocytic processes, in the vicinity and at a distance from the synaptic cleft (Danbolt et al., 1992; Levy et al., 1993; Rothstein et al., 1994; Torp et al., 1994; Chaudhry et al., 1995; Lehre et al., 1995). EAAT2 exists in at least three splice variants which differ only in their C-terminal domain. EAAT2a is the predominant variant, and represents ∼90%, whereas EAAT2b and EAAT2c represent ∼6% and ∼1% of total EAAT2 protein, respectively (Chen et al., 2002; Rauen et al., 2004; Holmseth et al., 2009). These variants have similar regional distribution and although they are all primarily expressed in astrocytes, they have also been detected in neurons (Schmitt et al., 2002; Chen et al., 2004; Maragakis et al., 2004; Bassan et al., 2008; Gonzalez-Gonzalez et al., 2008a; Holmseth et al., 2009). EAAT2a is more abundantly expressed than EAAT2b, and is a presynaptic glutamate transporter (Berger et al., 2005; Rimmele and Rosenberg, 2016). Within the hippocampus, 14–29% of axon terminals express EAAT2a (Chen et al., 2004). Though EAAT2a and EAAT2b share similar functional properties, they differ for the sequence of their extreme intracellular C-terminus (Chen et al., 2002; Sullivan et al., 2004). Unlike EAAT2a, EAAT2b has a PDZ binding domain that makes it capable of binding to proteins like PICK1, PSD95, and DLG1 (Bassan et al., 2008; Gonzalez-Gonzalez et al., 2008a; Underhill et al., 2015). These, in turn, can alter the currents mediated by the EAAT2b transporter (Sogaard et al., 2013). EAAT2a forms heteromers with EAAT2b, which have been proposed to stabilize EAAT2a around synapses (Haugeto et al., 1996; Peacey et al., 2009).

EAAT2 is highly mobile on the plasma membrane of astrocytes (D∗ = 0.15–0.23 μm2/s) (though a lower value of D∗ = 0.039 μm2/s has been measured using quantum dots; Al Awabdh et al., 2016), and the rate with which it diffuses along the plasma membrane can be increased by glutamate binding to EAAT2 or to AMPA, NMDA and metabotropic glutamate receptors, and can be reduced by blocking glutamate binding to EAAT2 (Benediktsson et al., 2012; Murphy-Royal et al., 2015; Michaluk et al., 2020). The surface diffusion of the EAAT2 variants EAAT2a and EAAT2b is more confined at astrocytic processes proximal to synapses, especially for EAAT2b (Al Awabdh et al., 2016). Consistent with previous work, glutamate increases the surface mobility of both EAAT2 variants, whereas blocking synaptic activity reduces it (Al Awabdh et al., 2016). The more confined diffusion of EAAT2b may be attributed to the presence of the PDZ domain, which allows EAAT2b to interact with scaffolding proteins and anchor it to macromolecular complexes that astrocytes form in subcellular domains opposite to neuronal presynaptic terminals (Al Awabdh et al., 2016). There is also evidence that membrane raft association regulates the targeting and function of glutamate transporters, especially for EAAT2 (Butchbach et al., 2004).

Glutamate transporters have been suggested to become incorporated into the plasma membrane through exocytosis (Cheng et al., 2002; Chowdhury et al., 2002; Robinson, 2002; Fournier et al., 2004; Karylowski et al., 2004; Zeigerer et al., 2004), and several components of this molecular machinery have been identified in astrocytes (Parpura et al., 1995; Hepp et al., 1999; Zhang et al., 2004). Consistent with these findings, calcium-dependent exocytosis of EAAT2 has been detected using FM dyes in cultured astrocytes (Stenovec et al., 2008). The same experiments showed that EAAT2 has a punctate distribution along the astrocytic plasma membrane, suggesting that the glutamate uptake capacity of these cells varies depending on the local density of expression of glutamate transporters (Stenovec et al., 2008). Interestingly, recent work indicate that the lifetime of EAAT2 on the astrocyte plasma membrane is ∼22 s (Michaluk et al., 2020). Whereas lateral diffusion could serve as a mechanism for transporter turnover away from synapses, where the diffusivity of these molecules is higher, endo/exocytosis from/to the plasma membrane to intracellular organelles could contribute to transporter turnover in astrocytic processes nearby synapses, where the diffusivity of these molecules is lower (Michaluk et al., 2020).

Although 80–90% of EAAT2 is localized in astrocytes, there is a small proportion (5–10%) in neuronal axon terminals (Rauen and Kanner, 1994; Torp et al., 1994; Schmitt et al., 1996; Torp et al., 1997; Chen et al., 2004; Furness et al., 2008; Melone et al., 2009, 2011, 2019). In neurons, EAAT2 co-localizes with the α1 and α3 isoforms of the Na+/K+-ATPase, but this co-localization is looser than that with the α2 isoform in astrocytes, suggesting a less efficient interaction between EAAT2 and the Na+/K+-ATPase in neurons (Melone et al., 2019). Neuronal EAAT2 appears to be required to provide glutamate to synaptic mitochondria, and is therefore linked to energy metabolism (Petr et al., 2015; Fischer et al., 2018; McNair et al., 2019, 2020; Sharma et al., 2019). By contrast, astrocytic EAAT2 is crucial to ensure survival, resistance to epilepsy, and prevent cognitive decline. Loss of neuronal and astrocytic EAAT2 have both implications on long-term memory and spatial reference learning, but the time scale over which they exert these effects is different (Sharma et al., 2019). Loss of astrocytic EAAT2 leads to early deficits, whereas loss of neuronal EAAT2 leads to late-onset deficits in long-term memory and spatial reference learning (Sharma et al., 2019). These findings are important because they identify neuronal and astrocytic EAAT2 as contributing to different aspects of cognitive function and, potentially, as different therapeutic targets in cognitive decline (Petr et al., 2015; Fischer et al., 2018; McNair et al., 2019, 2020; Sharma et al., 2019).

Multiple studies have shown that there are interesting relationships between astrocytic coverage, glutamate transporter expression and synaptic size (Ventura and Harris, 1999; Genoud et al., 2006; Witcher et al., 2007; Lushnikova et al., 2009; Witcher et al., 2010; Patrushev et al., 2013; Medvedev et al., 2014; Gavrilov et al., 2018; Herde et al., 2020). For example, in the rodent hippocampus, only 40–60% of synapses have astrocytic processes, and these cover only 53% of their perimeter (Ventura and Harris, 1999; Witcher et al., 2007, 2010). The size of a spine correlates with its release probability (Schikorski and Stevens, 1997). Astrocytes are closer to smaller spines (Medvedev et al., 2014), but the overall astrocytic coverage does not change with spine size (Gavrilov et al., 2018). Although there is less EAAT2 at smaller spines, its density is higher (Herde et al., 2020). These findings have important implications for understanding how glutamate transporters control spillover at synapses with different size (Scimemi et al., 2004), and the implications of this phenomenon on synaptic and astrocyte plasticity (Wenzel et al., 1991; Matsusaki et al., 2001; Bernardinelli et al., 2014; Perez-Alvarez et al., 2014).

Transcriptional, Translational, and Post-translational Regulation of Glutamate Transporters

Despite current agreements on the presence of EAAT2 in neurons, in the 1990s, some groups failed to find EAAT2 proteins in subsets of cortical neurons (Rothstein et al., 1994; Chaudhry et al., 1995; Lehre et al., 1995), in contrast to others (Torp et al., 1994; Schmitt et al., 1996; Torp et al., 1997). The discrepancy between these findings was attributed to the existence of a post-transcriptional and post-translational control of EAAT2 expression (Gegelashvili and Schousboe, 1997; Anderson and Swanson, 2000; Plachez et al., 2000). In fact, like most membrane proteins, glutamate transporters can be regulated at the gene expression, protein targeting and trafficking, and post-translational level.

The gene structure and organization of most glutamate transporters identified in the late 1990s showed that the promoter regions are highly conserved between mouse and human (Hagiwara et al., 1996; Stoffel et al., 1996). These regions do not contain a TATA box but a GC box and, in humans, an E box (Martinez-Lozada et al., 2016). The genes encoding different glutamate transporters contain different excision/splicing sites for different exons, which can generate variant mRNA species and proteins. Accordingly, multiple studies have reported the existence of several mRNA size classes encoding EAAT1 and EAAT3 (Pines et al., 1992; Tanaka, 1993; Mukainaka et al., 1995; Nakayama et al., 1996; Palos et al., 1996; Gegelashvili and Schousboe, 1997). This might be due to differences in polyadenylation and the existence of mRNAs with different coding capacity (Gegelashvili and Schousboe, 1997).

When glutamate transporters and their human homologs were first cloned, knowledge on the elements regulating their transcription largely relied on information collected from ASCT1, a neutral amino acid transporter of the same family of high affinity transporters as glutamate transporters (Hofmann et al., 1994). ASCT1 has 39–44% amino acid sequence identity, similar hydropathy profiles, trans-membrane organization and conservation of crucial function-related motifs compared to EAAT2 (Gegelashvili and Schousboe, 1997). According to these initial reports, the promoter region of EAAT2 was thought to contain at least five consensus sequences for the Sp1 transcription factor (krox24, krox20, Egr3, NGFI-C), involved in cell differentiation (Hofmann et al., 1994; Gegelashvili and Schousboe, 1997). By the early 2000’s, cloning and bioinformatics works established that the promoter region for EAAT1-2 is highly conserved: not only does it not have a TATA box, but lacks well-defined cis-elements and contains five consensus sequences for Sp1 and GC-rich repeats, also found in humans (Su et al., 2003). The search for regulatory transcription factors has led to the identification of the Nuclear Factor of Activated T cells (NFAT), the N-myc proto-oncogene protein (N-myc), and the Nuclear Factor κB (NF-κB), and a consensus NF-κB binding sequence in the 5′-UTR region of the Slc1a2 gene in humans (Meyer et al., 1996; Su et al., 2003). The Tumor Necrosis Factor α (TNFα), a cytokine involved in the acute phase of inflammatory reactions, decreases EAAT2 mRNA expression by increasing NF-κB activation (Su et al., 2003), perhaps by promoting NF-kB interactions with other transcription factors (Sitcheran et al., 2005). The ability of transcription factors to regulate gene expression can change the sensitivity of glutamate transporter expression to other regulatory proteins. For example, TNFα regulates the activity of the Yin Yang 1 (YY1) transcription factor which, when bound to the EAAT2 promoter, changes the effect of NF-κB from activation to suppression (Karki et al., 2014). In turn, NF-κB regulates YY1 expression. These findings suggest the existence of complex interplays between NF-κB and YY1 for the transcriptional regulation of EAAT2 expression.

Over the last two decades, other groups have identified factors, cis-regulatory elements and epigenetic mechanisms regulating EAAT1-2 transcription, but many unknowns remain about the molecular mechanisms regulating EAAT3-5 expression. In Table 1, we provide a summary of current studies on modulation of glutamate transporters listed in PubMed. One can easily note that in many cases, the results are conflicting. One may argue that inconsistencies are inevitable when studying a given transporter in different cell types and animal species. However, in some cases these considerations do not allow to resolve conflicting results from different laboratories. For this reason, in this review, we limit our discussion to forms of modulation of glutamate transporters for which some consensus exists.

TABLE 1 Regulating factors of glutamate transporter uptake and expression.

	
The table provides a summary of the results obtained in the literature regarding the mechanisms controlling the rate of glutamate uptake and the expression of glutamate transporters in a variety of animal models and expression systems. The cells in the first column of the table are color-coded to highlight studies focusing on glutamate uptake (light blue) or glutamate transporter expression (dark blue). The third column, labeled N/A, refers to studies that did not distinguish among different glutamate transporter subtypes. The cells in the last four columns are color-coded to highlight increases (green), decreases (orange), or no change (gray) in glutamate transporter uptake or expression. Abbreviations: mouse (ms), human (hum), cortex (cort), cerebellum (cereb), hippocampus (hipp), spinal cord (spin cord), astrocyte (astro), neuron (nrn), granule cell (gran), Schwann cells (Schwann), oocyte (ooc), retina (ret), retinoblastoma (retblast), synaptosome (synapt), arachidonic acid (AA), Bisindolylmaleimide (BIM), ω-conotoxin (ω-CTX), dehydroepiandrosterone (DHEA), phorbol 12-myristate 13-acetate (PMA), and 12-0-tetradecanoylphorbol-13-acetate (TPA).

There is a general agreement on the fact that in cultured neurons, PACAP, cAMP, and PKA-dependent pathways increase EAAT1 expression (Martinez-Lozada et al., 2016) and uptake (Hertz et al., 1978; Gegelashvili et al., 1996). Presumably this effect is mediated by activation of the transcription factor cAMP-response element binding protein (CREB), but the transcription factors or the cis elements of the promoter responsible for this effect have not been identified (Martinez-Lozada et al., 2016). This form of transcriptional regulation may provide a pathway through which activation of G-protein membrane receptors coupled to cAMP and PKA-dependent signaling pathways indirectly affect glutamate uptake, as it has been shown in other contexts for D2 dopamine receptors or α1 and β-adrenergic receptors (Kerkerian et al., 1987).

Stable epigenetic alterations of glutamate transporter gene expression are heritable in the short term, but do not involve DNA mutations. These include methylation and histone modifications, and there are multiple CpG regions in the promoter for EAAT2 where methylation can occur (Zschocke et al., 2005). One of the consequences of methylation is that it alters the ability of glucocorticoids to change EAAT2 expression. Accordingly, in the cerebellum, where the EAAT2 promoter is hyper-methylated, glucocorticoids are unable to change EAAT2 expression (Zschocke et al., 2005). By contrast, in the forebrain, where the EAAT2 promoter is hypo-methylated, glucocorticoid up-regulate EAAT2 expression (Zschocke et al., 2005).

Phosphorylation and glycosylation are two documented forms of post-translational modifications for glutamate transporters (Gegelashvili and Schousboe, 1997). Accordingly, increasing protein kinase C (PKC) activation by phorbol esters leads to increased phosphorylation of EAAT2 at the residue Ser113 and increased glutamate uptake (Roginski et al., 1993). N-glycosylation promotes EAAT3 expression, but has no effect on EAAT1 (Conradt et al., 1995; Ferrer-Martinez et al., 1995).

Arachidonic acid, produced via activation of NMDA receptors in neurons and metabotropic glutamate receptors in astrocytes, can directly interact with different types of glutamate transporters, with different effects. For example, it reduces glutamate uptake via EAAT1, enhances glutamate uptake via EAAT2 and leads to a moderate increase of glutamate uptake via EAAT3 (Chan et al., 1983; Volterra et al., 1992; Trotti et al., 1995). Arachidonic acid can lead to the activation of PKC, promoting glutamate uptake via EAAT2. Metabolites of arachidonic acid can be a source of reactive oxygen species (ROS), which inhibit glutamate uptake but increase the transporters’ steady state affinity for glutamate (Volterra et al., 1994b).

There is a growing awareness that these forms of regulation are complex not only because they likely differ among species, cell types and brain regions, but also because they interact with one another in ways that can be difficult to reproduce in reduced preparations but that affect the function of these transporters in vivo. These currently unknowns are likely going to be addressed by using experimental approaches that allow manipulation of different regulation factor in situ, and in a cell-specific manner.

Activity-Dependent Modulation of Glutamate Transporter Trafficking

The first observation that glutamate itself can modulate its uptake came from data showing that glutamate uptake is increased in astrocyte cultures supplemented with conditioned media from neuronal cultures (Drejer et al., 1983; Voisin et al., 1993). Pure astrocytic cultures only express EAAT1, but co-culture of neurons and astrocytes increases EAAT1 expression and induces EAAT2 expression (Gegelashvili and Schousboe, 1997; Swanson et al., 1997). This effect depends on p42/44 MAP kinases activation via the tyrphostin-sensitive Receptor Tyrosine Kinase (RTK) signaling pathway, and is abolished by inhibitors of PI3K, tyrosine kinase and NF-kB (Swanson et al., 1997; Zelenaia et al., 2000). Similarly, decreased glutamate uptake via EAAT1-2 (not EAAT3) occurs in response to axotomy of glutamatergic neurons of cortical lesions (McGeer et al., 1977; Shifman, 1991; Ginsberg et al., 1995; Levy et al., 1995). Together, these forms of activity-dependent regulation of EAAT2 expression allow this transporter to be more abundant and less mobile in astrocytic processes close to active glutamatergic synapses, an effect that can provide an effective strategy to limit glutamate spillover away from the synaptic cleft.

Similarly, to glutamate, glutamate transporter substrates like D-Aspartate and ligands like L-trans-PDC and TBOA can also produce a redistribution of EAAT1 on the cell membrane (Shin et al., 2009). Consistent with these findings, treating astrocyte cultures with kainate, dbcAMP or AMPA receptor agonists increases D-aspartate uptake and EAAT1 protein expression (Gegelashvili et al., 1996). It is unclear whether these effects are due to binding to AMPA receptors or are due to release of diffusible molecules (e.g., arachidonic acid, diacylglycerol, nitric oxide) through more complex intracellular signaling cascades (Gegelashvili and Schousboe, 1997).

Physiological Roles of Glutamate Transporters

The role of glutamate transporters in regulation of phasic and tonic extracellular glutamate levels is critical for neuronal signaling and controlling excitotoxicity (Rothstein et al., 1996). Spillover of glutamate and inter-synaptic cross-talk have been associated with multiple neuropsychiatric disorders, including schizophrenia, epilepsy, addiction, depression and obsessive compulsive disorder (O’Donovan et al., 2017; Bellini et al., 2018; Malik and Willnow, 2019). Knock-out mouse models of different subtypes of glutamate transporters have revealed major motor deficits with decreased levels of glial transporters EAAT1-2 (Rothstein et al., 1996), with more subtle behavioral deficits with loss of the neuronal transporter EAAT3 (Peghini et al., 1997; Bellini et al., 2018).

In humans, decreased expression and reduced function of EAAT2 are associated with amyotrophic lateral sclerosis (ALS) (Rothstein et al., 1995; Bruijn et al., 1997; Rosenblum and Trotti, 2017). In transgenic mice expressing an N-terminal fragment of mutant huntingtin (R6/2), there is an age-dependent downregulation of EAAT2, which leads to a progressive increase in the extracellular glutamate (Behrens et al., 2002). Other glutamate transporters, however, remain unchanged, suggesting that EAAT2-mediated excitotoxicity might contribute to Huntington’s disease (Behrens et al., 2002). In the few identified polymorphisms of the gene encoding EAAT3, dicarboxylic aminoaciduria, a deficit in kidney function was prominent, as well as family linkage to schizophrenia and obsessive–compulsive disorders (OCD) (Bailey et al., 2011; Porton et al., 2013). In mice, loss or increased EAAT3 are associated with increased anxiety and OCD-like behaviors, suggesting that preserving an optimal expression of this transporter is key for the function of neuronal circuits affected by this disease (Zike et al., 2017; Bellini et al., 2018; Delgado-Acevedo et al., 2019). Significant lower levels of EAAT2 have also been reported in vitro (Scimemi et al., 2013) and in vivo, in animal models of Alzheimer’s disease (Wilson et al., 2003; Dabir et al., 2006; Mookherjee et al., 2011; Schallier et al., 2011; Hefendehl et al., 2016), as well as in humans affected by this disease (Li et al., 1997; Jacob et al., 2007; Scott et al., 2011; Leng et al., 2021), whereas promoting EAAT2 expression improves cognitive function (Fan et al., 2018). Several mutations in the gene that encodes EAAT1 have also been linked to the neurological disease Episodic Ataxia Type 6 (Choi et al., 2017; Chivukula et al., 2020). The most well-studied mutation (P290R) results in reduced glutamate transport activity and a large increase in the uncoupled anion conductance, the latter property being suggested to be responsible for the phenotype in studies using a Drosophila melanogaster model (Winter et al., 2012; Parinejad et al., 2016). Further understanding of how these transporters are regulated in specific circuits and synapses may allow for design of therapeutics that correct for specific deficits in transporter function.

GABA Transporters

In mammals, GABA transporters are classified into four subtypes, based on amino acid sequence homology and pharmacological properties. These include GAT1-3 and the betaine GABA transporter BGT1. Out of these, GAT1 and GAT3 account for the largest proportion of GABA uptake in the CNS, and for this reason, they will be the focus of our attention in this review. Structural information of the GABA transporters comes from prokaryote homologs such as LeuTAa (Figure 2; Yamashita et al., 2005). In the neocortex, GAT1 is expressed robustly in GABAergic axon terminals, astrocytic processes, oligodendrocytes and microglial cells (Fattorini et al., 2020). The expression of GAT1 is pronounced in the axon terminal of chandelier GABAergic neurons (known as “cartridges”), which provide inhibitory inputs to the axon initial segment of pyramidal cells (Woo et al., 1998). In young mice (P9), GAT1 is also transiently expressed somatically, but this somatic expression is lost in juvenile mice (P29) (Yan et al., 1997; Yan and Ribak, 1998). Presynaptic boutons in the cerebellum and hippocampus express 800–1,300 μm–2 GAT1 molecules, with a preferential perisynaptic localization (Chiu et al., 2002; Melone et al., 2015). These density values drop to 640 μm–2 GAT1 molecules along the length of the axon (Chiu et al., 2002), whereas the surface density of GAT1 in astrocytic membranes is 3.5 times higher than in axon terminals (Melone et al., 2015). GAT3 is mainly localized in peri-synaptic astrocytic processes, but has also been detected in brainstem and cortical neurons (Clark et al., 1992; Melone et al., 2003, 2005, 2015). These findings are important because they provide anatomical evidence to the fact that no GABA transporter can be described as being purely neuronal or glial, although they may have a preferential distribution in a given cell type depending on the age and brain region of different animal models.

FIGURE 2 Crystal structure of LeuTAA, a bacterial homolog of GABA transporters (PDB: 2A65). (A) Side view of the LeuTAa transporter parallel to the membrane, using a ribbon (top) and a surface representation sliced through the center of the transporter (bottom). (B) As in (A), viewed from the extracellular side of the membrane. Leu (magenta), sodium (blue), and chloride ions (green) are represented as spheres. (C) Summary of the main feature of the stoichiometric and non-stoichiometric current mediated by Leu and GABA transporters in prokaryotes and eukaryotes, respectively. Image generated using The PyMOL Molecular Graphics System (Version 2.3.2; Schrödinger, 2010).

Both GAT1 and GAT3 transporters translocate the zwitterion GABA across the membrane by coupling its movement to the co-transport of two Na+ and one Cl– ion, leading to the net influx of one positive charge per transport cycle (1 GABA: 2 Na+: 1 Cl–) (Radian and Kanner, 1983; Keynan and Kanner, 1988). In addition to this stoichiometric current, GABA transporters mediate an agonist-independent leak current carried by alkali ions, which can be detected in mammalian expression systems but not in Xenopus laevis oocytes (Cammack and Schwartz, 1996; Eckstein-Ludwig et al., 1999; Lu and Hilgemann, 1999; MacAulay et al., 2002; Matthews et al., 2009). This current can generate a local change in membrane voltage and/or membrane resistance, which can be more or less pronounced depending on the magnitude and direction of the driving force for the permeant ions and the local density of the transporters. Changes in membrane resistance are important because they act as a local shunt capable of hampering action potential propagation and cell excitability.

As in the case of glutamate transporters, we provide a summary of current studies on modulation of GABA transporters listed in PubMed (Table 2).

TABLE 2 Regulating factors of GABA transporter Uptake and expression.

	
The table provides a summary of the results obtained in the literature regarding mechanisms controlling the rate of GABA Uptake and its expression in a variety of animal models and expression systems. The color coding of each cell and abbreviations are as described for Table 1. SNr, substantia nigra pars reticulata; ACHC, cis-1,3-aminocyclohexane carboxylic acid; CPA, α-cyclopiazonic acid; 5,7-DHT, 5,7-dihydroxytryptamine; OAG, oleyl-acetyl glycerol; PDD, 4 alpha-phorbol-12,13-didecanoate.

The Surface Mobility and Cellular Distribution of GAT1

The GABA transporter GAT1 has a membrane pool of 61–63% (Chiu et al., 2002). Fluorescence Recovery After Photobleaching (FRAP) experiments in neuroblastoma 2a cells show that 50% of membrane GAT1 is immobile, likely due to the existence of tight interactions between GAT1 and the actin cytoskeleton, mediated by the adaptor protein ezrin (Imoukhuede et al., 2009). Accordingly, depolymerizing actin or interrupting the GAT1 PDZ-interacting domain increases the transporter mobility, whereas depolymerizing microtubules does not (Imoukhuede et al., 2009). Numerous mechanisms contribute to cycle this pool of transporter to and from the plasma membrane. Specifically, there are two regions in the C-terminal domain of GAT1 that are responsible for supporting GAT1 export from the endoplasmic reticulum and for putting GAT1 under the control of the exocyst (Farhan et al., 2004; Moss et al., 2009). In addition to these, the MAGUK protein Pals1 is co-expressed with GAT1 in COS7 cells and contributes to stabilize GAT1 on the cell membrane (McHugh et al., 2004).

Regulation of GABA Uptake

The control of GABA uptake can be expressed through changes in the rate with which GABA transporters are trafficked and redistributed in the plasma membrane, with consequences on the number of transporter molecules available for binding extracellular GABA, or by modulating the biophysical properties of GABA transporters (e.g., Vmax, km, etc.). Neurons regulate the surface expression of GAT1 in parallel with that of extracellular neurotransmitter levels. GABA transporters interact with the SNARE proteins syntaxin 1A and Munc-18 through molecular interactions modulated by PKC (Beckman et al., 1998; Deken et al., 2000; Geerlings et al., 2001; Horton and Quick, 2001). These transporters are associated with presynaptic vesicles similar to synaptic vesicles, capable of undergoing clathrin-mediated internalization and endosomal sorting (Barbaresi et al., 2001). Despite being morphologically similar to synaptic vesicles, and despite the fact that they can be released at similar rates in a calcium dependent manner, they lack synaptophysin and vesicular GABA transporters (Deken et al., 2003). It has been suggested that these GABA transporter-containing vesicles might represent a population of endocytic or exocytic vesicles acting as cargos for the assembly of synaptic domains distinct from the active zone (Deken et al., 2003).

PKC modulation is important to change the number of functional GABA transporters expressed on the plasma membrane (Corey et al., 1994; Quick et al., 1997). In Xenopus laevis oocytes, PKC activation with PMA promotes GAT1 translocation to the cell membrane at low basal GAT1 expression levels, but this effect is not detected at high levels of expression of GAT1. The rate of GABA uptake can also be altered by PKC (Corey et al., 1994; Quick et al., 1997). Accordingly, inhibiting PKC reduces GABA uptake through a reduction of Vmax (not km), whereas inhibiting protein phosphatase 2B increases it. These forms of PKC-dependent modulation differ in cultured neurons and isolated nerve terminals, where surface expression of GAT1 is decreased by PKC dependent phosphorylation (Beckman et al., 1999; Wang and Quick, 2005; Cristovao-Ferreira et al., 2009).

Another protein kinase, PKA, stimulates GABA transport via GAT1 and activates a GAT1-mediated cationic current during opioid withdrawal (Bagley et al., 2005). This enhanced PKA signaling contributes to increase neuronal action potential firing rates in opioid-sensitive PAG neurons during opioid withdrawal (Bagley et al., 2005).

In the area CA1 of the rat hippocampus, chronic stimulation of cannabinoid receptors CB1/2 reduces GAT1 gene expression (Higuera-Matas et al., 2012). Conversely, an endogenous agonist of endocannabinoid receptors, 2-arachidonoylglycerol (2-AG), increases GABA uptake (Romero et al., 1998; Venderova et al., 2005). CB1 receptors have been suggested to interact or co-localize with β2 adrenergic receptors (Hudson et al., 2010), the activation of which also increases GAT1 expression and GABA uptake (Martins et al., 2018). The ability of β2 adrenergic receptors to promote GABA uptake (and that of β1 adrenergic receptors to inhibit it) are mediated by a PKA pathway controlled by cannabinoid receptors, because the modulation of GABA update by adrenergic receptors is inhibited by the cannabinoid receptor agonist WIN55,212-2 (Martins et al., 2018).

In astrocytes, GABA uptake via GAT1, not GAT3, is modulated by neurotrophic factors like BDNF (Vaz et al., 2011). This is due to the ability of BDNF to inhibit dynamin/clathrin-dependent constitutive internalization of GAT1, effectively increasing the lifetime of GAT1 on the cell membrane. The effect of BDNF is mediated by activation of a truncated form of the TrkB receptor, is coupled to a PLC-γ/PKC-δ and ERK/MAPK pathway, and requires activation of adenosine A2A receptors (Vaz et al., 2011). The cross talk between A2A receptors and BDNF is likely due to the fact that activation of A2A receptors activates TrkB and induces its translocation to lipid rafts (Tebano et al., 2008; Assaife-Lopes et al., 2010). This type of modulation differs in neurons, where BDNF can still inhibit GABA uptake via GAT1 in conjunction with A2A receptors, but here the BDNF modulation persists in the presence of A2A receptor antagonists or upon removal of extracellular adenosine (Vaz et al., 2008).

Physiological Roles of GABA Transporters

Genetic variants in the solute carrier family 6 member 1 (SLC6A1) gene, encoding GAT1, are associated with various neurodevelopmental disorders, including epilepsy with myoclonic atonic seizures, autism spectrum disorder and intellectual disability (Bhat et al., 2020; Goodspeed et al., 2020). Knockout mouse models of GAT1, as well as GAT1 inhibitors, have shown a range of physiological effects that indicate that GAT1, through its exquisite regulation of GABA in the brain, may be an interesting target for therapies for neuropsychiatric diseases (Salat and Kulig, 2011; Egawa and Fukuda, 2013; Bhat et al., 2020). GAT1 inhibitors, such as tiagabine, NO-711 and DDPM-2571, have anti-seizure, antinociceptive, antiallodynic and anxiolytic properties (Laughlin et al., 2002; Todorov et al., 2005; Pakulska, 2007; Xu et al., 2008; Salat et al., 2017). Loss of GAT1 in the nucleus accumbens has also been observed in mice treated with chronic social defeat stress paralleling observations in patients with major depressive disorder (MDD) (Heshmati et al., 2020).

During epileptic seizures, the ionic gradient that typically supports GABA uptake from the extracellular space can be dissipated or even inverted, promoting GABA release through the reversed activity of GABA transporters like GAT3 (Raiteri et al., 2002; Wu et al., 2003; Richerson and Wu, 2004; Kinney, 2005). Under these conditions, the reversal of GABA uptake could provide a useful mechanism to curtail seizure propagation. With some exceptions (Xie et al., 2017), single nucleotide polymorphisms in SLC6A11, the gene encoding human GAT3, have been detected in patients with antiepileptic drug resistance (Kim et al., 2011). It is possible that a dysfunction of GAT3 could alter both phasic and tonic GABAergic transmission in the epileptic brain.

GATs regulate neurotransmission in other complex ways. As mentioned above, substrate transport through GAT elicits an inward current that can directly excite neurons (Bagley et al., 2005, 2011). GAT1 also generates a sodium-dependent capacitive current that can also contribute to shunting (Mager et al., 1993). Efflux of GABA into the extracellular space contributes to tonic currents mediated by GABAA receptors in hippocampal neurons (Wu et al., 2007) and glia (Barakat and Bordey, 2002). Tonic currents are critical in neurodevelopment (Egawa and Fukuda, 2013) and are increased in pathological conditions, such as inflammation (Tonsfeldt et al., 2016). Regulation of GAT activity and trafficking has a dramatic effect on tonic currents, especially those mediated by extrasynaptic GABAA receptors (Scimemi et al., 2005; Scimemi, 2014a,b). In addition to controlling integration of inputs onto GABAergic neurons, these tonic currents control the coincidence detection window of excitatory inputs onto pyramidal neurons (Sylantyev et al., 2020) and contribute to regulation of dopamine release in the dorsal striatum (Roberts et al., 2020). GAT3 activity in astrocytes regulates release of ATP and adenosine that contributes to heterosynaptic depression in the hippocampus (Boddum et al., 2016), highlighting an additional mechanism for regulating synaptic activity.

Dopamine Uptake: One Transporter, Three Currents, Multiple Regulation Sites

Dopamine uptake via the membrane transporter DAT is stoichiometrically coupled to the co-transport of two Na+ and one Cl– ion (Figure 3) (Krueger, 1990; McElvain and Schenk, 1992; Gu et al., 1994; Penmatsa et al., 2013, 2015). Voltage-clamp recordings of DAT-mediated currents in Xenopus oocytes, however, show that the mean net charge to dopamine ratio is significantly larger than the one predicted by the stoichiometric coupling ratio (Sonders et al., 1997; Ingram et al., 2002). This discrepancy can be accounted for by the fact that DAT, like glutamate and GABA transporters (as well as serotonin and norepinephrine transporters; Bruns et al., 1993; Cammack et al., 1994; Mager et al., 1994; Galli et al., 1995; Jayanthi et al., 2002), also mediates two stoichiometrically uncoupled conductances: one that requires dopamine binding to the transporter, and one that does not and is constitutively active. For simplicity, we refer to them as the uncoupled and the leak conductance, respectively.

FIGURE 3 Crystal structure of Drosophila melanogaster dDAT dopamine transporter (PDB: 4XP1). (A) Side view of the Drosophila dopamine transporter parallel to the membrane, using a ribbon (top) and a surface representation sliced through the center of the transporter (bottom). (B) As in A, viewed from the extracellular side of the membrane. L-Dopa (magenta), sodium (blue) and chloride ions (green) are represented as spheres. (C) Summary of the main feature of the stoichiometric and non-stoichiometric current mediated by LeuT (prokaryotic dopamine transporter homolog) and DAT transporters in eukaryotes, respectively. Image generated using The PyMOL Molecular Graphics System (Version 2.3.2; Schrödinger, 2010).

It is interesting to note that the concentration of dopamine required for half-maximal transport is ∼580 nM, whereas the one required for activation of the uncoupled current is only ∼35 nM (Ingram et al., 2002). The extracellular concentration of dopamine in the brain has been known to vary on a sub-second time scale due to phasic firing of dopaminergic neurons, and to be modulated by administration of substances of abuse. Until recently, fast-scan cyclic voltammetry (FSCV) has been considered the technique that provides the best combination of temporal resolution, sensitivity and chemical selectivity (Roberts et al., 2013), but even in this case it has been traditionally used to obtain relative, as opposed to absolute values of dopamine concentrations in the brain. In 2018, the development of cellular-scale probes have enabled stable recording of sub-second extracellular dopamine oscillations (Schwerdt et al., 2018). Although the recorded levels of dopamine were specific for each mouse, they ranged between 40–450 nM (Schwerdt et al., 2018). This means that the uncoupled DAT current is likely to be a main contributor to cell excitability and neurotransmitter release in DAT-expressing neurons. The uncoupled DAT-mediated current is carried by chloride and, surprisingly, its activation increases cell excitability in cultured dopaminergic neurons (Ingram et al., 2002; Carvelli et al., 2004).

In physiological conditions, the leak current is carried by K+ and perhaps H+ ions. This leak current is voltage-dependent, outward-rectifying and reverses at ∼–10 mV (Sonders et al., 1997). Although its activation does not require ion or agonist binding to the transporter, it can be blocked by dopamine and other DAT ligands. The ability of substrates to block the leak current is not consistently observed among other members of the Na+/Cl–-dependent cotransporter family, with the exception of GAT1 (Mager et al., 1994; Cammack and Schwartz, 1996; MacAulay et al., 2002; Kanner, 2003) and the serotonin (Mager et al., 1994) and norepinephrine transporters (Galli et al., 1995). These findings identify multiple mechanisms through which dopamine transporters can change the membrane potential and the signaling properties of neurons through mechanisms that are distinct from its ability to take up dopamine from the extracellular space.

A summary of current studies on modulation of dopamine transporters listed in PubMed is provided in Table 3.

TABLE 3 Regulating factors of dopamine transporter Uptake and expression.

	
The table provides a summary of the results obtained in the literature regarding the mechanisms controlling the rate of dopamine uptake and its expression in a variety of animal models and expression systems. The color coding of each cell and abbreviations are as described for Table 1. NAc, nucleus accumbens; AMPH, amphetamine; CPE, carboxypeptidase E; 4HA, 4-Hydroxyamphetamine; IBMX, 3-isobutyl-1-methylxanthine; METH, methamphetamine; MPD, methylphenidate; PEA, phenylethylamine; PP2, protein phosphatase 2.

The Pharmacology of Dopamine Transporters

DAT is a target of psychostimulants like cocaine and amphetamine. Cocaine binds to DAT and increases extracellular dopamine levels by blocking its transport activity (Chen and Reith, 2000; Norregaard and Gether, 2001; Goldberg et al., 2003; Torres et al., 2003). In contrast, amphetamine is a substrate for this transporter (Kahlig et al., 2005). The inward transport of amphetamine increases the number of inward-facing transporter binding sites, which results in an increased rate of dopamine efflux through what at first sight may look like an exchange process (Sulzer et al., 1995; Kahlig et al., 2005). In reality, this phenomenon may be more complex, as evidenced by the fact that N-terminus phosphorylation of DAT alters only the amphetamine-induced dopamine efflux without altering dopamine uptake (Khoshbouei et al., 2004). Dopamine and amphetamine are both substrates for DAT, and compete with each other for binding to the transporter (Sulzer et al., 1993; Hoffman et al., 1998). They can both trigger dopamine efflux through reversed uptake, by inverting the electrochemical gradient for Na+ and Cl– (Sitte et al., 1998). Whereas dopamine inhibits the DAT channel-like behavior, amphetamine activates it. This effect is not due to differences in the ability of dopamine and amphetamine to change the intracellular Na+ concentration, because it can still be detected in outside-out patches, where the intracellular Na+ concentration is controlled (Kahlig et al., 2005).

The Surface Mobility and Cellular Distribution of Dopamine Transporters

Dopamine transporters are monoamine neurotransmitter transporters located in the pre-synaptic terminal of dopaminergic neurons, away from the synaptic area (Nirenberg et al., 1997). These cells are located in the ventral tegmental area and substantia nigra, project to the cingulate and medial pre-frontal cortex, nucleus accumbens, olfactory tubercle, lateral habenula, and striatum. Through their axonal projections, dopaminergic neurons control motivation, reward reinforcement and movement, in addition to attention, planning and memory. Therefore, the regulation of DAT function has extensive functional implications for all these behaviors. It is now evident that the role of DAT is not limited to regulating the extracellular concentration of dopamine but is also involved in the homeostatic maintenance of presynaptic function (Torres et al., 2003). Like other membrane proteins, DAT is associated with intracellular proteins that ensure the appropriate location of the transporter in specific domains of the cell membrane at a given time. Accordingly, DAT has been shown to bind to the SNARE protein complex syntaxin 1A (Lee et al., 2004), the PDZ domain protein PICK1 (Torres et al., 2001; Bjerggaard et al., 2004), CaMKII (Fog et al., 2006), and the multiple-LIM-domain-containing adaptor protein HIC-5 (Carneiro et al., 2002).

DAT is equally distributed in and out of rafts (Foster et al., 2008), nanometer-wide and temporally dynamic lipid microdomains enriched in cholesterol, sphingolipids and glycosylphosphatidylinositol (GPI)-anchored proteins (Hancock, 2006). Structural studies of the Drosophila melanogaster DAT (dDAT) reveal that cholesterol can bind in a crevice formed by transmembrane domains 5, 7, and 1a, which is thought to prevent the conformational changes required for the transporter to transition from outward-facing to inward-facing (Penmatsa et al., 2013, 2015). This is in agreement with functional studies that show DAT can be regulated by cholesterol, due to its ability to promote an outward-facing conformation of the transporter (Hong and Amara, 2010; Jones et al., 2012).

By using Fluorescence Correlation Spectroscopy (FCS) and FRAP, Adkins et al. (2007) measured the surface diffusion coefficient of DAT in two types of cells: HEK293 and N2a cells. Due to differences in laser beam waist and sampling areas between FRAP and FCS, FCS is better suited to detect fast protein movements within a confined domain, whereas FRAP allows to detect long-range diffusion between domains in the membrane (Adkins et al., 2007). In HEK293 cells, DAT diffuses with a diffusion coefficient of 3.6 × 10–9 cm2/s, consistent with a relatively freely diffusible protein. This diffusion coefficient is lower in N2a cells, where DAT is partially immobilized (D < 10–10 cm2/s). This difference is likely due to the existence of cell-specific direct or indirect interactions between DAT and cytoskeletal proteins or with membrane rafts. Accordingly, single particle tracking studies confirm that the median diffusion coefficient for DAT is 1.6 × 10–10 cm2/s in Flp-In 293 cells (Kovtun et al., 2015).

Overall, these findings indicate that DAT transporters diffuse substantially slower and in a more confined manner than the glutamate transporter GLT-1, probably because of the presence of different types of protein interactions in different membrane transporters or because of the presence/lack of specific interacting substrates (Murphy-Royal et al., 2015).

Transcriptional, Translational, and Post-translational Regulation of Dopamine Transporters

The human DAT gene was first cloned in 1991, and it is localized to chromosome 5p15.3 and has a single transcriptional start site (Kilty et al., 1991; Vandenbergh et al., 1992a,b). DAT has a half-life of about 2 days on the cell membrane, suggesting the existence of dynamic processes of transcriptional and translational regulation (Kimmel et al., 2000; Kahlig and Galli, 2003). Transcription factors like Nurr1 and Pitx3 have an expression pattern that match that of dopaminergic neurons, and are known to be crucial for the development, survival and maintenance of midbrain dopaminergic neurons (Lee et al., 2010; Rodriguez-Traver et al., 2016; Salemi et al., 2016). Accordingly, disrupting the Nurr1 gene alters the development of dopaminergic neurons (Zetterstrom et al., 1997; Castillo et al., 1998; Saucedo-Cardenas et al., 1998). Nurr1 binds with high-affinity to an NGFI-B responsive element within the promoter regions of DAT and other dopamine-related genes (Sacchetti et al., 1999). The ability of Nurr1 to increase DAT expression, however, relies on mechanisms that are independent of the NGFI-B responsive element. There are a variety of sequence motifs identified through in silico studies, which point to the fact that DAT can be regulated epigenetically via DNA methylation and histone acetylation in vitro and in vivo (Wang et al., 2007). Like other housekeeping genes, the DAT gene lacks conserved TATA and CAAT boxes (confirming that DAT is susceptible to regulation by histone acetylation), and its core promoter is GC-rich (confirming that DAT expression can be regulated via DNA methylation) (Choi and Kim, 2008).

These discoveries prompted a number of biochemical and mutagenesis studies on heterologous expression systems, which led to the identification of key structural features and functional domains of the transporter. A major breakthrough occurred when the first X-ray crystal structure of the bacterial leucine transporter LeuTAa, which shares 20–25% homology with all monoamine transporters was solved at 1.65 Å resolution (Yamashita et al., 2005). This was followed by the structure of Drosophila melanogaster DAT, which shares 50–55% homology with monoamine transporters (Penmatsa et al., 2013, 2015; Wang et al., 2015). Together, these studies suggest that all monoamine transporters have 12 α-helix spanning domains and an alternating access substrate translocation mechanism (Kristensen et al., 2011). Despite the structural similarity of the core transmembrane regions of all monoamine transporters, their extracellular loops, N- and C-termini differ significantly in length and sequence (Kristensen et al., 2011). This is important because these regions are the site of post-translational modifications and can be the site of protein–protein interactions that control transporter localization, stability and activity (Aggarwal and Mortensen, 2017). Post-translational modifications, binding partner interactions, modulation by cholesterol and membrane raft associations are all capable of modulating DAT activity and ultimately dopamine clearance from the extracellular space.

The N-terminus of the DAT protein is subject to phosphorylation and ubiquitination (Karam and Javitch, 2018). Although five serine residues at positions 2, 4, 7, 12, 13 have been identified as targets for phosphorylation by PKC, the only verified phosphorylation site is Ser7 (Moritz et al., 2013). The localization of these sites at the distal end of a long and flexible domain suggests that these residues may be also regulated by partner interactions, but these effects have not been demonstrated. A second verified phosphorylation site is Thr53, which is followed by a Pro residue, making it specific for proline-directed kinases such as ERK. Thr53 is also flanked by an SH3 domain, which is a ligand for protein scaffolding (Saksela and Permi, 2012). In between these two phosphorylation sites, Lys27 is a residue that undergoes ubiquitination catalyzed by the ubiquitin E3 ligases Nedd4-2 and Parkin. This modification is increased by PKC activation and contributes to promote DAT endocytosis (Hong and Amara, 2010; Vina-Vilaseca and Sorkin, 2010). The N-terminal domain also contains binding sites for the regulatory partners syntaxin 1 (res 1–33, which reduces dopamine uptake) and D2 dopamine receptors (res. 1–15) (Lee et al., 2007; Binda et al., 2008; Carvelli et al., 2008). On the C-terminal domain of the DAT protein, Cys580 provides an S-palmitoylation site, and a FREK motif at residues 587–590 binds the small Ras-like GTPase Rin1 and contributes to PKC-mediated endocytosis (Boudanova et al., 2008b; Navaroli et al., 2011). Other regulatory domains in the C-terminal region include binding sites for CaMK (res. 612–617) and α-synuclein (res. 606–620) (Lee et al., 2001; Moszczynska et al., 2007). The C-terminal domain also contains a PDZ domain-binding sequence, where interactions with scaffolding proteins like PICK1 occur. Notably, these interactions are neither necessary nor sufficient for surface targeting of DAT, and have yet unidentified functional consequences (Bjerggaard et al., 2004). Other members of the “DAT interactome” include PP2Ac (Baumann et al., 2000), Hic-5 (Carneiro et al., 2002), RACK (Lee et al., 2004), D2 dopamine receptors (Bolan et al., 2007), flotillin-1 (Cremona et al., 2011), Rin (Navaroli et al., 2011), and the k-opioid receptor (Kivell et al., 2014; Bermingham and Blakely, 2016).

The regulatory mechanisms described so far make it easy to spot that protein kinases like PKC, one of the best characterized regulatory proteins for DAT, can regulate dopamine uptake through a variety of processes, including an endocytotic mechanism driven by the phosphorylation of DAT accessory proteins, a kinetic down-regulation mediated by Ser7 phosphorylation, and an increased dopamine efflux mediated by altered surface transporter activity. Together, these modifications allow PKC to reduce dopamine uptake. The actions of PKC are opposite to those induced by palmitoylation, which lead to reduced DAT degradation (Chen et al., 2013). It is important to keep in mind that the primary sites of PKC-stimulated phosphorylation are the membrane rafts, the microdomains rich in cholesterol and sphingolipids. Therefore, changing PKC-mediated phosphorylation of DAT can affect its raft distribution and protein interactions. In contrast to PKC, ERK provides a tonic mechanism to increase dopamine uptake perhaps via phosphorylation of Thr53 (Foster et al., 2012). In addition to PKC and ERK, there is a host of other kinases that are capable of regulating DAT activity, including PKA, PKG, CaMKII, MAPK, PI3K/Akt and tyrosine kinases. PKCβ may also be involved in the mechanism of D2 receptor regulation of DAT by ERK (Chen et al., 2013).

Physiological Roles of Dopamine Transporters

DAT regulates extracellular concentrations of the neuromodulator dopamine and thus, subsequent activation of dopamine receptors that can enhance or inhibit neurons. DAT is the target of psychoactive and psychotherapeutic drugs such as methylphenidate and amphetamines that are used in treatment of attention deficit and hyperactivity disorder (ADHD) symptoms, as well as drugs of abuse (Schmitt et al., 2013; German et al., 2015). Genetic variants of SLC6A3, the gene encoding DAT in humans, have been identified in patients with neuropsychiatric, neurodevelopmental and neurodegenerative disorders (Mazei-Robison et al., 2005; Serretti and Mandelli, 2008; Mick and Faraone, 2009; Sakrikar et al., 2012; Bowton et al., 2014; Hansen et al., 2014; Mergy et al., 2014; Herborg et al., 2018; Campbell et al., 2019; DiCarlo et al., 2019). Studies of these variants have observed deficits in uptake, transporter-associated currents, trafficking and regulation (Gowrishankar et al., 2014). Further studies of these mutants should give more insight into the complex regulation of dopamine-modulated circuits. An intriguing new area is the role that DAT plays in transport of ligands that act on the trace amine-associated receptor subtype 1 (Taar1), an intracellularly localized G protein-coupled receptor that can, in turn, regulate internalization of both the DAT and EAAT3 in dopaminergic neurons (Underhill et al., 2014, 2019), enhancing extrasynaptic glutamate signaling (Li et al., 2017). Taar1 is known to regulate monoaminergic signaling and dysregulation of TAAR1 signaling may play important roles in neuropsychiatric disorders (Schwartz et al., 2018; Dodd et al., 2020).

Conclusion

Transporters for excitatory, inhibitory, and modulatory neurotransmitters like glutamate, GABA and dopamine are complex molecular machines that do much more than act as vacuums that clear neurotransmitters out of the extracellular space. This complexity arises in part from the core biophysical properties of these transporters, which are capable of generating different types of ionic currents. The additional levels of complexity comes from the fact that their residence time on the membrane, their trafficking from intracellular compartments and their kinetics can be modulated at different levels, including transcriptional, epigenetic, translational and post-translational levels. All these forms of modulation can change across species, cell types and brain regions. Since these regulatory mechanisms also change over time, their efficacy likely follows the metabolic state of a given neuron or astrocyte. The knowledge accumulated over the last few years and the growth of novel experimental approaches will undoubtedly provide new insights into cell-specific changes in the way the activity of neurotransmitter transporters can control cell excitability and metabolism across the brain.

Author Contributions

RMR and SLI wrote the manuscript. AS wrote the manuscript and coordinated the investigative team. All authors contributed to the article and approved the submitted version.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

We performed detailed PubMed searches to include information listed in Tables 1–3. We apologize to authors of any work we might have missed.

Funding. This work was supported by the Australian National Health and Medical Research Council Project grant APP1164494 to RMR, NIH grant R01 DA042565 to SLI, and NSF grants IOS1655365 and IOS2011998 to AS.
==== Refs
References

Adkins E. M. Samuvel D. J. Fog J. U. Eriksen J. Jayanthi L. D. Vaegter C. B. (2007). Membrane mobility and microdomain association of the dopamine transporter studied with fluorescence correlation spectroscopy and fluorescence recovery after photobleaching. Biochemistry 46 10484–10497. 10.1021/bi700429z 17711354
Adolph O. Koster S. Rath M. Georgieff M. Weigt H. U. Engele J. (2007). Rapid increase of glial glutamate uptake via blockade of the protein kinase A pathway. Glia 55 1699–1707. 10.1002/glia.20583 17886291
Aggarwal S. Mortensen O. V. (2017). Overview of monoamine transporters. Curr. Protoc. Pharmacol. 79 12.16.1–12.16.17. 10.1002/cpph.32 29261228
Al Awabdh S. Gupta-Agarwal S. Sheehan D. F. Muir J. Norkett R. Twelvetrees A. E. (2016). Neuronal activity mediated regulation of glutamate transporter GLT-1 surface diffusion in rat astrocytes in dissociated and slice cultures. Glia 64 1252–1264. 10.1002/glia.22997 27189737
Anderson B. B. Chen G. Gutman D. A. Ewing A. G. (1998). Dopamine levels of two classes of vesicles are differentially depleted by amphetamine. Brain Res. 788 294–301. 10.1016/s0006-8993(98)00040-7 9555063
Anderson C. M. Swanson R. A. (2000). Astrocyte glutamate transport: review of properties, regulation, and physiological functions. Glia 32 1–14. 10.1002/1098-1136(200010)32:1<1::aid-glia10>3.0.co;2-w 10975906
Anderson J. G. Cooney P. T. Erikson K. M. (2007). Brain manganese accumulation is inversely related to gamma-amino butyric acid uptake in male and female rats. Toxicol. Sci. 95 188–195. 10.1093/toxsci/kfl130 17032702
Anderson J. G. Fordahl S. C. Cooney P. T. Weaver T. L. Colyer C. L. Erikson K. M. (2008). Manganese exposure alters extracellular GABA, GABA receptor and transporter protein and mRNA levels in the developing rat brain. Neurotoxicology 29 1044–1053. 10.1016/j.neuro.2008.08.002 18771689
Arriza J. L. Fairman W. A. Wadiche J. I. Murdoch G. H. Kavanaugh M. P. Amara S. G. (1994). Functional comparisons of three glutamate transporter subtypes cloned from human motor cortex. J. Neurosci. 14 5559–5569. 10.1523/jneurosci.14-09-05559.1994 7521911
Assaife-Lopes N. Sousa V. C. Pereira D. B. Ribeiro J. A. Chao M. V. Sebastiao A. M. (2010). Activation of adenosine A2A receptors induces TrkB translocation and increases BDNF-mediated phospho-TrkB localization in lipid rafts: implications for neuromodulation. J. Neurosci. 30 8468–8480. 10.1523/jneurosci.5695-09.2010 20573894
Bagley E. E. Gerke M. B. Vaughan C. W. Hack S. P. Christie M. J. (2005). GABA transporter currents activated by protein kinase A excite midbrain neurons during opioid withdrawal. Neuron 45 433–445. 10.1016/j.neuron.2004.12.049 15694329
Bagley E. E. Hacker J. Chefer V. I. Mallet C. McNally G. P. Chieng B. C. (2011). Drug-induced GABA transporter currents enhance GABA release to induce opioid withdrawal behaviors. Nat. Neurosci. 14 1548–1554. 10.1038/nn.2940 22037500
Bahena-Trujillo R. Arias-Montano J. A. (1999). [3H] gamma-aminobutyric acid transport in rat substantia nigra pars reticulata synaptosomes: pharmacological characterization and phorbol ester-induced inhibition. Neurosci. Lett. 274 119–122. 10.1016/s0304-3940(99)00692-8 10553952
Bailey C. G. Ryan R. M. Thoeng A. D. Ng C. King K. Vanslambrouck J. M. (2011). Loss-of-function mutations in the glutamate transporter SLC1A1 cause human dicarboxylic aminoaciduria. J. Clin. Invest. 121 446–453. 10.1172/jci44474 21123949
Barakat L. Bordey A. (2002). GAT-1 and reversible GABA transport in Bergmann glia in slices. J. Neurophysiol. 88 1407–1419. 10.1152/jn.2002.88.3.1407 12205162
Barbaresi P. Gazzanelli G. Malatesta M. (2001). gamma-Aminobutyric acid transporters in the cat periaqueductal gray: a light and electron microscopic immunocytochemical study. J. Comp. Neurol. 429 337–354. 10.1002/1096-9861(20000108)429:2<337::aid-cne12>3.0.co;2-z 11116224
Bassan M. Liu H. Madsen K. L. Armsen W. Zhou J. Desilva T. (2008). Interaction between the glutamate transporter GLT1b and the synaptic PDZ domain protein PICK1. Eur. J. Neurosci. 27 66–82. 10.1111/j.1460-9568.2007.05986.x 18184314
Baumann M. H. Ayestas M. A. Dersch C. M. Brockington A. Rice K. C. Rothman R. B. (2000). Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: therapeutic implications. Synapse 36 102–113. 10.1002/(sici)1098-2396(200005)36:2<102::aid-syn3>3.0.co;2-# 10767057
Beckman M. L. Bernstein E. M. Quick M. W. (1998). Protein kinase C regulates the interaction between a GABA transporter and syntaxin 1A. J. Neurosci. 18 6103–6112. 10.1523/jneurosci.18-16-06103.1998 9698305
Beckman M. L. Bernstein E. M. Quick M. W. (1999). Multiple G protein-coupled receptors initiate protein kinase C redistribution of GABA transporters in hippocampal neurons. J. Neurosci. 19 :RC9 .
Behrens P. F. Franz P. Woodman B. Lindenberg K. S. Landwehrmeyer G. B. (2002). Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. Brain 125 1908–1922. 10.1093/brain/awf180 12135980
Bellini S. Fleming K. E. De M. McCauley J. P. Petroccione M. A. D’Brant L. Y. (2018). Neuronal glutamate transporters control dopaminergic signaling and compulsive behaviors. J. Neurosci. 38 937–961. 10.1523/jneurosci.1906-17.2017 29229708
Benediktsson A. M. Marrs G. S. Tu J. C. Worley P. F. Rothstein J. D. Bergles D. E. (2012). Neuronal activity regulates glutamate transporter dynamics in developing astrocytes. Glia 60 175–188. 10.1002/glia.21249 22052455
Berger U. V. DeSilva T. M. Chen W. Rosenberg P. A. (2005). Cellular and subcellular mRNA localization of glutamate transporter isoforms GLT1a and GLT1b in rat brain by in situ hybridization. J. Comp. Neurol. 492 78–89. 10.1002/cne.20737 16175560
Bergles D. E. Tzingounis A. V. Jahr C. E. (2002). Comparison of coupled and uncoupled currents during glutamate uptake by GLT-1 transporters. J. Neurosci. 22 10153–10162. 10.1523/jneurosci.22-23-10153.2002 12451116
Bermingham D. P. Blakely R. D. (2016). Kinase-dependent regulation of monoamine neurotransmitter transporters. Pharmacol. Rev. 68 888–953. 10.1124/pr.115.012260 27591044
Bernabe A. Mendez J. A. Hernandez-Kelly L. C. Ortega A. (2003). Regulation of the Na+-dependent glutamate/aspartate transporter in rodent cerebellar astrocytes. Neurochem. Res. 28 1843–1849.14649726
Bernardinelli Y. Randall J. Janett E. Nikonenko I. Konig S. Jones E. V. (2014). Activity-dependent structural plasticity of perisynaptic astrocytic domains promotes excitatory synapse stability. Curr. Biol. 24 1679–1688. 10.1016/j.cub.2014.06.025 25042585
Bernstein E. M. Quick M. W. (1999). Regulation of gamma-aminobutyric acid (GABA) transporters by extracellular GABA. J. Biol. Chem. 274 889–895. 10.1074/jbc.274.2.889 9873028
Berry C. B. Hayes D. Murphy A. Wiessner M. Rauen T. McBean G. J. (2005). Differential modulation of the glutamate transporters GLT1, GLAST and EAAC1 by docosahexaenoic acid. Brain Res. 1037 123–133. 10.1016/j.brainres.2005.01.008 15777760
Bhat S. El-Kasaby A. Freissmuth M. Sucic S. (2020). Functional and biochemical consequences of disease variants in neurotransmitter transporters: a special emphasis on folding and trafficking deficits. Pharmacol. Ther. 2020 :107785 . 10.1016/j.pharmthera.2020.107785 33310157
Binda F. Dipace C. Bowton E. Robertson S. D. Lute B. J. Fog J. U. (2008). Syntaxin 1A interaction with the dopamine transporter promotes amphetamine-induced dopamine efflux. Mol. Pharmacol. 74 1101–1108. 10.1124/mol.108.048447 18617632
Bjerggaard C. Fog J. U. Hastrup H. Madsen K. Loland C. J. Javitch J. A. (2004). Surface targeting of the dopamine transporter involves discrete epitopes in the distal C terminus but does not require canonical PDZ domain interactions. J. Neurosci. 24 7024–7036. 10.1523/jneurosci.1863-04.2004 15295038
Boddum K. Jensen T. P. Magloire V. Kristiansen U. Rusakov D. A. Pavlov I. (2016). Astrocytic GABA transporter activity modulates excitatory neurotransmission. Nat. Commun. 7 :13572 .
Bohmer C. Philippin M. Rajamanickam J. Mack A. Broer S. Palmada M. (2004). Stimulation of the EAAT4 glutamate transporter by SGK protein kinase isoforms and PKB. Biochem. Biophys. Res. Commun. 324 1242–1248. 10.1016/j.bbrc.2004.09.193 15504348
Bolan E. A. Kivell B. Jaligam V. Oz M. Jayanthi L. D. Han Y. (2007). D2 receptors regulate dopamine transporter function via an extracellular signal-regulated kinases 1 and 2-dependent and phosphoinositide 3 kinase-independent mechanism. Mol. Pharmacol. 71 1222–1232. 10.1124/mol.106.027763 17267664
Boudanova E. Navaroli D. M. Melikian H. E. (2008a). Amphetamine-induced decreases in dopamine transporter surface expression are protein kinase C-independent. Neuropharmacology 54 605–612. 10.1016/j.neuropharm.2007.11.007 18164041
Boudanova E. Navaroli D. M. Stevens Z. Melikian H. E. (2008b). Dopamine transporter endocytic determinants: carboxy terminal residues critical for basal and PKC-stimulated internalization. Mol. Cell Neurosci. 39 211–217. 10.1016/j.mcn.2008.06.011 18638559
Boudker O. Ryan R. M. Yernool D. Shimamoto K. Gouaux E. (2007). Coupling substrate and ion binding to extracellular gate of a sodium-dependent aspartate transporter. Nature 445 387–393. 10.1038/nature05455 17230192
Bowton E. Saunders C. Reddy I. A. Campbell N. G. Hamilton P. J. Henry L. K. (2014). SLC6A3 coding variant Ala559Val found in two autism probands alters dopamine transporter function and trafficking. Transl. Psychiatry 4 :e464 . 10.1038/tp.2014.90 25313507
Brosnan J. T. Brosnan M. E. (2013). Glutamate: a truly functional amino acid. Amino Acids 45 413–418. 10.1007/s00726-012-1280-4 22526238
Bruijn L. I. Becher M. W. Lee M. K. Anderson K. L. Jenkins N. A. Copeland N. G. (1997). ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 18 327–338. 10.1016/s0896-6273(00)80272-x 9052802
Bruns D. Engert F. Lux H. D. (1993). A fast activating presynaptic reuptake current during serotonergic transmission in identified neurons of Hirudo. Neuron 10 559–572. 10.1016/0896-6273(93)90159-o 8386524
Bull N. D. Barnett N. L. (2002). Antagonists of protein kinase C inhibit rat retinal glutamate transport activity in situ. J. Neurochem. 81 472–480. 10.1046/j.1471-4159.2002.00819.x 12065656
Butchbach M. E. Tian G. Guo H. Lin C. L. (2004). Association of excitatory amino acid transporters, especially EAAT2, with cholesterol-rich lipid raft microdomains: importance for excitatory amino acid transporter localization and function. J. Biol. Chem. 279 34388–34396. 10.1074/jbc.m403938200 15187084
Cammack J. N. Rakhilin S. V. Schwartz E. A. (1994). A GABA transporter operates asymmetrically and with variable stoichiometry. Neuron 13 949–960. 10.1016/0896-6273(94)90260-7 7524562
Cammack J. N. Schwartz E. A. (1996). Channel behavior in a gamma-aminobutyrate transporter. Proc. Natl. Acad. Sci. U.S.A. 93 723–727. 10.1073/pnas.93.2.723 8570623
Campbell N. G. Shekar A. Aguilar J. I. Peng D. Navratna V. Yang D. (2019). Structural, functional, and behavioral insights of dopamine dysfunction revealed by a deletion in SLC6A3. Proc. Natl. Acad. Sci. U.S.A. 116 3853–3862. 10.1073/pnas.1816247116 30755521
Canul-Tec J. C. Assal R. Cirri E. Legrand P. Brier S. Chamot-Rooke J. (2017). Structure and allosteric inhibition of excitatory amino acid transporter 1. Nature 544 446–451. 10.1038/nature22064 28424515
Carneiro A. M. Ingram S. L. Beaulieu J. M. Sweeney A. Amara S. G. Thomas S. M. (2002). The multiple LIM domain-containing adaptor protein Hic-5 synaptically colocalizes and interacts with the dopamine transporter. J. Neurosci. 22 7045–7054. 10.1523/jneurosci.22-16-07045.2002 12177201
Carvelli L. Blakely R. D. DeFelice L. J. (2008). Dopamine transporter/syntaxin 1A interactions regulate transporter channel activity and dopaminergic synaptic transmission. Proc. Natl. Acad. Sci. U.S.A. 105 14192–14197. 10.1073/pnas.0802214105 18768815
Carvelli L. McDonald P. W. Blakely R. D. DeFelice L. J. (2004). Dopamine transporters depolarize neurons by a channel mechanism. Proc. Natl. Acad. Sci. U.S.A. 101 16046–16051. 10.1073/pnas.0403299101 15520385
Carvelli L. Moron J. A. Kahlig K. M. Ferrer J. V. Sen N. Lechleiter J. D. (2002). PI 3-kinase regulation of dopamine uptake. J. Neurochem. 81 859–869. 10.1046/j.1471-4159.2002.00892.x 12065645
Casado M. Bendahan A. Zafra F. Danbolt N. C. Aragon C. Gimenez C. (1993). Phosphorylation and modulation of brain glutamate transporters by protein kinase C. J. Biol. Chem. 268 27313–27317. 10.1016/s0021-9258(19)74251-3 7903307
Castillo S. O. Baffi J. S. Palkovits M. Goldstein D. S. Kopin I. J. Witta J. (1998). Dopamine biosynthesis is selectively abolished in substantia nigra/ventral tegmental area but not in hypothalamic neurons in mice with targeted disruption of the Nurr1 gene. Mol. Cell Neurosci. 11 36–46. 10.1006/mcne.1998.0673 9608532
Cater R. J. Vandenberg R. J. Ryan R. M. (2014). The domain interface of the human glutamate transporter EAAT1 mediates chloride permeation. Biophys. J. 107 621–629. 10.1016/j.bpj.2014.05.046 25099801
Cater R. J. Vandenberg R. J. Ryan R. M. (2016). Tuning the ion selectivity of glutamate transporter-associated uncoupled conductances. J. Gen. Physiol. 148 13–24. 10.1085/jgp.201511556 27296367
Cervinski M. A. Foster J. D. Vaughan R. A. (2005). Psychoactive substrates stimulate dopamine transporter phosphorylation and down-regulation by cocaine-sensitive and protein kinase C-dependent mechanisms. J. Biol. Chem. 280 40442–40449. 10.1074/jbc.m501969200 16204245
Chan P. H. Kerlan R. Fishman R. A. (1983). Reductions of gamma-aminobutyric acid and glutamate uptake and (Na+ + K+)-ATPase activity in brain slices and synaptosomes by arachidonic acid. J. Neurochem. 40 309–316. 10.1111/j.1471-4159.1983.tb11284.x 6130123
Chang M. Y. Lee S. H. Kim J. H. Lee K. H. Kim Y. S. Son H. (2001). Protein kinase C-mediated functional regulation of dopamine transporter is not achieved by direct phosphorylation of the dopamine transporter protein. J. Neurochem. 77 754–761. 10.1046/j.1471-4159.2001.00284.x 11331404
Chaudhry F. A. Lehre K. P. van Lookeren Campagne M. Ottersen O. P. Danbolt N. C. Storm-Mathisen J. (1995). Glutamate transporters in glial plasma membranes: highly differentiated localizations revealed by quantitative ultrastructural immunocytochemistry. Neuron 15 711–720. 10.1016/0896-6273(95)90158-2 7546749
Chen I. Pant S. Wu Q. Cater R. Sobti M. Vandenberg R. J. (2021). Glutamate transporters contain a conserved chloride channel with two hydrophobic gates. bioRxiv [Preprint], 10.1101/2020.05.25.115360
Chen N. Reith M. E. (2000). Structure and function of the dopamine transporter. Eur. J. Pharmacol. 405 329–339.11033338
Chen R. Daining C. P. Sun H. Fraser R. Stokes S. L. Leitges M. (2013). Protein kinase Cbeta is a modulator of the dopamine D2 autoreceptor-activated trafficking of the dopamine transporter. J. Neurochem. 125 663–672. 10.1111/jnc.12229 23458603
Chen R. Furman C. A. Zhang M. Kim M. N. Gereau R. W. T. Leitges M. (2009). Protein kinase Cbeta is a critical regulator of dopamine transporter trafficking and regulates the behavioral response to amphetamine in mice. J. Pharmacol. Exp. Ther. 328 912–920. 10.1124/jpet.108.147959 19098163
Chen T. Tanaka M. Wang Y. Sha S. Furuya K. Chen L. (2017). Neurosteroid dehydroepiandrosterone enhances activity and trafficking of astrocytic GLT-1 via sigma1 receptor-mediated PKC activation in the hippocampal dentate gyrus of rats. Glia 65 1491–1503. 10.1002/glia.23175 28581152
Chen W. Aoki C. Mahadomrongkul V. Gruber C. E. Wang G. J. Blitzblau R. (2002). Expression of a variant form of the glutamate transporter GLT1 in neuronal cultures and in neurons and astrocytes in the rat brain. J. Neurosci. 22 2142–2152. 10.1523/jneurosci.22-06-02142.2002 11896154
Chen W. Mahadomrongkul V. Berger U. V. Bassan M. DeSilva T. Tanaka K. (2004). The glutamate transporter GLT1a is expressed in excitatory axon terminals of mature hippocampal neurons. J. Neurosci. 24 1136–1148. 10.1523/jneurosci.1586-03.2004 14762132
Cheng C. Glover G. Banker G. Amara S. G. (2002). A novel sorting motif in the glutamate transporter excitatory amino acid transporter 3 directs its targeting in Madin-Darby canine kidney cells and hippocampal neurons. J. Neurosci. 22 10643–10652. 10.1523/jneurosci.22-24-10643.2002 12486157
Cheng M. H. Torres-Salazar D. Gonzalez-Suarez A. D. Amara S. G. Bahar I. (2017). Substrate transport and anion permeation proceed through distinct pathways in glutamate transporters. eLife 6 :e25850 .
Chi L. Reith M. E. (2003). Substrate-induced trafficking of the dopamine transporter in heterologously expressing cells and in rat striatal synaptosomal preparations. J. Pharmacol. Exp. Ther. 307 729–736. 10.1124/jpet.103.055095 12975490
Chiu C. S. Jensen K. Sokolova I. Wang D. Li M. Deshpande P. (2002). Number, density, and surface/cytoplasmic distribution of GABA transporters at presynaptic structures of knock-in mice carrying GABA transporter subtype 1-green fluorescent protein fusions. J. Neurosci. 22 10251–10266. 10.1523/jneurosci.22-23-10251.2002 12451126
Chivukula A. S. Suslova M. Kortzak D. Kovermann P. Fahlke C. (2020). Functional consequences of SLC1A3 mutations associated with episodic ataxia 6. Hum. Mutat. 41 1892–1905. 10.1002/humu.24089 32741053
Choi J. K. Kim Y. J. (2008). Epigenetic regulation and the variability of gene expression. Nat. Genet. 40 141–147. 10.1038/ng.2007.58 18227874
Choi K. D. Jen J. C. Choi S. Y. Shin J. H. Kim H. S. Kim H. J. (2017). Late-onset episodic ataxia associated with SLC1A3 mutation. J. Hum. Genet. 62 443–446. 10.1038/jhg.2016.137 27829685
Chowdhury H. H. Kreft M. Zorec R. (2002). Rapid insulin-induced exocytosis in white rat adipocytes. Pflugers Arch. 445 352–356. 10.1007/s00424-002-0938-2 12466937
Clark J. A. Deutch A. Y. Gallipoli P. Z. Amara S. G. (1992). Functional expression and CNS distribution of a beta-alanine-sensitive neuronal GABA transporter. Neuron 9 337–348. 10.1016/0896-6273(92)90172-a 1497897
Conradt M. Stoffel W. (1997). Inhibition of the high-affinity brain glutamate transporter GLAST-1 via direct phosphorylation. J. Neurochem. 68 1244–1251. 10.1046/j.1471-4159.1997.68031244.x 9048771
Conradt M. Storck T. Stoffel W. (1995). Localization of N-glycosylation sites and functional role of the carbohydrate units of GLAST-1, a cloned rat brain L-glutamate/L-aspartate transporter. Eur. J. Biochem. 229 682–687. 10.1111/j.1432-1033.1995.0682j.x 7758463
Copeland B. J. Vogelsberg V. Neff N. H. Hadjiconstantinou M. (1996). Protein kinase C activators decrease dopamine uptake into striatal synaptosomes. J. Pharmacol. Exp. Ther. 277 1527–1532.8667219
Cordeiro J. M. Meireles S. M. Vale M. G. Oliveira C. R. Goncalves P. P. (2000). Ca(2+) regulation of the carrier-mediated gamma-aminobutyric acid release from isolated synaptic plasma membrane vesicles. Neurosci. Res. 38 385–395. 10.1016/s0168-0102(00)00193-0 11164565
Corey J. L. Davidson N. Lester H. A. Brecha N. Quick M. W. (1994). Protein kinase C modulates the activity of a cloned gamma-aminobutyric acid transporter expressed in Xenopus oocytes via regulated subcellular redistribution of the transporter. J. Biol. Chem. 269 14759–14767. 10.1016/s0021-9258(17)36690-5 8182081
Cremona M. L. Matthies H. J. Pau K. Bowton E. Speed N. Lute B. J. (2011). Flotillin-1 is essential for PKC-triggered endocytosis and membrane microdomain localization of DAT. Nat. Neurosci. 14 469–477. 10.1038/nn.2781 21399631
Cristovao-Ferreira S. Navarro G. Brugarolas M. Perez-Capote K. Vaz S. H. Fattorini G. (2013). A1R-A2AR heteromers coupled to Gs and G i/0 proteins modulate GABA transport into astrocytes. Purinerg. Signal. 9 433–449. 10.1007/s11302-013-9364-5 23657626
Cristovao-Ferreira S. Vaz S. H. Ribeiro J. A. Sebastiao A. M. (2009). Adenosine A2A receptors enhance GABA transport into nerve terminals by restraining PKC inhibition of GAT-1. J. Neurochem. 109 336–347. 10.1111/j.1471-4159.2009.05963.x 19200339
Dabir D. V. Robinson M. B. Swanson E. Zhang B. Trojanowski J. Q. Lee V. M. (2006). Impaired glutamate transport in a mouse model of tau pathology in astrocytes. J. Neurosci. 26 644–654. 10.1523/jneurosci.3861-05.2006 16407562
Dall’Igna O. P. Bobermin L. D. Souza D. O. Quincozes-Santos A. (2013). Riluzole increases glutamate uptake by cultured C6 astroglial cells. Int. J. Dev. Neurosci. 31 482–486. 10.1016/j.ijdevneu.2013.06.002 23777615
Danbolt N. C. (2001). Glutamate uptake. Prog. Neurobiol. 65 1–105.11369436
Danbolt N. C. Storm-Mathisen J. Kanner B. I. (1992). An [Na+ + K+]coupled L-glutamate transporter purified from rat brain is located in glial cell processes. Neuroscience 51 295–310. 10.1016/0306-4522(92)90316-t 1465194
Daniels G. M. Amara S. G. (1999). Regulated trafficking of the human dopamine transporter. Clathrin-mediated internalization and lysosomal degradation in response to phorbol esters. J. Biol. Chem. 274 35794–35801. 10.1074/jbc.274.50.35794 10585462
Davis K. E. Straff D. J. Weinstein E. A. Bannerman P. G. Correale D. M. Rothstein J. D. (1998). Multiple signaling pathways regulate cell surface expression and activity of the excitatory amino acid carrier 1 subtype of Glu transporter in C6 glioma. J. Neurosci. 18 2475–2485. 10.1523/jneurosci.18-07-02475.1998 9502808
Dehnes Y. Chaudhry F. A. Ullensvang K. Lehre K. P. Storm-Mathisen J. Danbolt N. C. (1998). The glutamate transporter EAAT4 in rat cerebellar Purkinje cells: a glutamate-gated chloride channel concentrated near the synapse in parts of the dendritic membrane facing astroglia. J. Neurosci. 18 3606–3619. 10.1523/jneurosci.18-10-03606.1998 9570792
Deken S. L. Beckman M. L. Boos L. Quick M. W. (2000). Transport rates of GABA transporters: regulation by the N-terminal domain and syntaxin 1A. Nat. Neurosci. 3 998–1003. 10.1038/79939 11017172
Deken S. L. Wang D. Quick M. W. (2003). Plasma membrane GABA transporters reside on distinct vesicles and undergo rapid regulated recycling. J. Neurosci. 23 1563–1568. 10.1523/jneurosci.23-05-01563.2003 12629157
Delgado-Acevedo C. Estay S. F. Radke A. K. Sengupta A. Escobar A. P. Henriquez-Belmar F. (2019). Behavioral and synaptic alterations relevant to obsessive-compulsive disorder in mice with increased EAAT3 expression. Neuropsychopharmacology 44 1163–1173. 10.1038/s41386-018-0302-7 30622300
DiCarlo G. E. Aguilar J. I. Matthies H. J. Harrison F. E. Bundschuh K. E. West A. (2019). Autism-linked dopamine transporter mutation alters striatal dopamine neurotransmission and dopamine-dependent behaviors. J. Clin. Invest. 129 3407–3419. 10.1172/jci127411 31094705
Divito C. B. Borowski J. E. Glasgow N. G. Gonzalez-Suarez A. D. Torres-Salazar D. Johnson J. W. (2017). Glial and neuronal glutamate transporters differ in the Na(+) requirements for activation of the substrate-independent anion conductance. Front. Mol. Neurosci. 10 :150 . 10.3389/fnmol.2017.00150 28611584
Dodd S. Carvalho A. F. Puri B. K. Maes M. Bortolasci C. C. Morris G. (2020). Trace amine-associated receptor 1 (TAAR1): a new drug target for psychiatry? Neurosci. Biobehav. Rev. 120 537–541. 10.1016/j.neubiorev.2020.09.028 33031817
Doolen S. Zahniser N. R. (2001). Protein tyrosine kinase inhibitors alter human dopamine transporter activity in Xenopus oocytes. J. Pharmacol. Exp. Ther. 296 931–938.11181926
Dowd L. A. Robinson M. B. (1996). Rapid stimulation of EAAC1-mediated Na+-dependent L-glutamate transport activity in C6 glioma cells by phorbol ester. J. Neurochem. 67 508–516. 10.1046/j.1471-4159.1996.67020508.x 8764574
Drejer J. Meier E. Schousboe A. (1983). Novel neuron-related regulatory mechanisms for astrocytic glutamate and GABA high affinity uptake. Neurosci. Lett. 37 301–306. 10.1016/0304-3940(83)90448-2 6136941
Eckstein-Ludwig U. Fei J. Schwarz W. (1999). Inhibition of uptake, steady-state currents, and transient charge movements generated by the neuronal GABA transporter by various anticonvulsant drugs. Br. J. Pharmacol. 128 92–102. 10.1038/sj.bjp.0702794 10498839
Egawa K. Fukuda A. (2013). Pathophysiological power of improper tonic GABA(A) conductances in mature and immature models. Front. Neural Circ. 7 :170 . 10.3389/fncir.2013.00170 24167475
Eliasof S. Jahr C. E. (1996). Retinal glial cell glutamate transporter is coupled to an anionic conductance. Proc. Natl. Acad. Sci. U.S.A. 93 4153–4158. 10.1073/pnas.93.9.4153 8633032
Eriksen J. Rasmussen S. G. Rasmussen T. N. Vaegter C. B. Cha J. H. Zou M. F. (2009). Visualization of dopamine transporter trafficking in live neurons by use of fluorescent cocaine analogs. J. Neurosci. 29 6794–6808. 10.1523/jneurosci.4177-08.2009 19474307
Espinoza-Rojo M. Lopez-Bayghen E. Ortega A. (2000). GLAST: gene expression regulation by phorbol esters. Neuroreport 11 2827–2832. 10.1097/00001756-200008210-00043 10976971
Fairman W. A. Vandenberg R. J. Arriza J. L. Kavanaugh M. P. Amara S. G. (1995). An excitatory amino-acid transporter with properties of a ligand-gated chloride channel. Nature 375 599–603. 10.1038/375599a0 7791878
Fan H. P. Fan F. J. Bao L. Pei G. (2006). SNAP-25/syntaxin 1A complex functionally modulates neurotransmitter gamma-aminobutyric acid reuptake. J. Biol. Chem. 281 28174–28184. 10.1074/jbc.m601382200 16861228
Fan S. Xian X. Li L. Yao X. Hu Y. Zhang M. (2018). Ceftriaxone improves cognitive function and upregulates GLT-1-related glutamate-glutamine cycle in APP/PS1 mice. J. Alzheimers Dis. 66 1731–1743. 10.3233/jad-180708 30452416
Fang H. Huang Y. Zuo Z. (2006). Enhancement of substrate-gated Cl- currents via rat glutamate transporter EAAT4 by PMA. Am. J. Physiol. Cell Physiol. 290 C1334–C1340.16601148
Fang Q. Hu W. W. Wang X. F. Yang Y. Lou G. D. Jin M. M. (2014). Histamine up-regulates astrocytic glutamate transporter 1 and protects neurons against ischemic injury. Neuropharmacology 77 156–166. 10.1016/j.neuropharm.2013.06.012 23791559
Farhan H. Korkhov V. M. Paulitschke V. Dorostkar M. M. Scholze P. Kudlacek O. (2004). Two discontinuous segments in the carboxyl terminus are required for membrane targeting of the rat gamma-aminobutyric acid transporter-1 (GAT1). J. Biol. Chem. 279 28553–28563. 10.1074/jbc.m307325200 15073174
Fattorini G. Melone M. Conti F. (2020). A reappraisal of GAT-1 localization in Neocortex. Front. Cell Neurosci. 14 :9 . 10.3389/fncel.2020.00009 32116556
Ferrer-Martinez A. Felipe A. Nicholson B. Casado J. Pastor-Anglada M. McGivan J. (1995). Induction of the high-affinity Na(+)-dependent glutamate transport system XAG- by hypertonic stress in the renal epithelial cell line NBL-1. Biochem. J. 310(Pt 2) , 689–692. 10.1042/bj3100689 7654212
Figiel M. Maucher T. Rozyczka J. Bayatti N. Engele J. (2003). Regulation of glial glutamate transporter expression by growth factors. Exp. Neurol. 183 124–135. 10.1016/s0014-4886(03)00134-1 12957496
Fischer J. F. Cho A. K. (1979). Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model. J. Pharmacol. Exp. Ther. 208 203–209.762652
Fischer K. D. Houston A. C. W. Desai R. I. Doyle M. R. Bergman J. Mian M. (2018). Behavioral phenotyping and dopamine dynamics in mice with conditional deletion of the glutamate transporter GLT-1 in neurons: resistance to the acute locomotor effects of amphetamine. Psychopharmacology 235 1371–1387. 10.1007/s00213-018-4848-1 29468294
Fog J. U. Khoshbouei H. Holy M. Owens W. A. Vaegter C. B. Sen N. (2006). Calmodulin kinase II interacts with the dopamine transporter C terminus to regulate amphetamine-induced reverse transport. Neuron 51 417–429. 10.1016/j.neuron.2006.06.028 16908408
Foster J. D. Adkins S. D. Lever J. R. Vaughan R. A. (2008). Phorbol ester induced trafficking-independent regulation and enhanced phosphorylation of the dopamine transporter associated with membrane rafts and cholesterol. J. Neurochem. 105 1683–1699. 10.1111/j.1471-4159.2008.05262.x 18248623
Foster J. D. Yang J. W. Moritz A. E. Challasivakanaka S. Smith M. A. Holy M. (2012). Dopamine transporter phosphorylation site threonine 53 regulates substrate reuptake and amphetamine-stimulated efflux. J. Biol. Chem. 287 29702–29712. 10.1074/jbc.m112.367706 22722938
Fournier K. M. Gonzalez M. I. Robinson M. B. (2004). Rapid trafficking of the neuronal glutamate transporter, EAAC1: evidence for distinct trafficking pathways differentially regulated by protein kinase C and platelet-derived growth factor. J. Biol. Chem. 279 34505–34513. 10.1074/jbc.m404032200 15197183
Furman C. A. Chen R. Guptaroy B. Zhang M. Holz R. W. Gnegy M. (2009). Dopamine and amphetamine rapidly increase dopamine transporter trafficking to the surface: live-cell imaging using total internal reflection fluorescence microscopy. J. Neurosci. 29 3328–3336. 10.1523/jneurosci.5386-08.2009 19279270
Furness D. N. Dehnes Y. Akhtar A. Q. Rossi D. J. Hamann M. Grutle N. J. (2008). A quantitative assessment of glutamate uptake into hippocampal synaptic terminals and astrocytes: new insights into a neuronal role for excitatory amino acid transporter 2 (EAAT2). Neuroscience 157 80–94. 10.1016/j.neuroscience.2008.08.043 18805467
Galli A. DeFelice L. J. Duke B. J. Moore K. R. Blakely R. D. (1995). Sodium-dependent norepinephrine-induced currents in norepinephrine-transporter-transfected HEK-293 cells blocked by cocaine and antidepressants. J. Exp. Biol. 198 2197–2212.7500004
Gamboa C. Ortega A. (2002). Insulin-like growth factor-1 increases activity and surface levels of the GLAST subtype of glutamate transporter. Neurochem. Int. 40 397–403. 10.1016/s0197-0186(01)00106-1 11821146
Ganel R. Crosson C. E. (1998). Modulation of human glutamate transporter activity by phorbol ester. J. Neurochem. 70 993–1000. 10.1046/j.1471-4159.1998.70030993.x 9489718
Garaeva A. A. Guskov A. Slotboom D. J. Paulino C. (2019). A one-gate elevator mechanism for the human neutral amino acid transporter ASCT2. Nat. Commun. 10 :3427 .
Garaeva A. A. Oostergetel G. T. Gati C. Guskov A. Paulino C. Slotboom D. J. (2018). Cryo-EM structure of the human neutral amino acid transporter ASCT2. Nat. Struct. Mol. Biol. 25 515–521. 10.1038/s41594-018-0076-y 29872227
Garcia B. G. Wei Y. Moron J. A. Lin R. Z. Javitch J. A. Galli A. (2005). Akt is essential for insulin modulation of amphetamine-induced human dopamine transporter cell-surface redistribution. Mol. Pharmacol. 68 102–109. 10.1124/mol.104.009092 15795321
Garcia-Tardon N. Gonzalez-Gonzalez I. M. Martinez-Villarreal J. Fernandez-Sanchez E. Gimenez C. Zafra F. (2012). Protein kinase C (PKC)-promoted endocytosis of glutamate transporter GLT-1 requires ubiquitin ligase Nedd4-2-dependent ubiquitination but not phosphorylation. J. Biol. Chem. 287 19177–19187. 10.1074/jbc.m112.355909 22505712
Gavrilov N. Golyagina I. Brazhe A. Scimemi A. Turlapov V. Semyanov A. (2018). Astrocytic coverage of dendritic spines, dendritic shafts, and axonal boutons in hippocampal neuropil. Front. Cell Neurosci. 12 :248 . 10.3389/fncel.2018.00248 30174590
Geerlings A. Nunez E. Lopez-Corcuera B. Aragon C. (2001). Calcium- and syntaxin 1-mediated trafficking of the neuronal glycine transporter GLYT2. J. Biol. Chem. 276 17584–17590. 10.1074/jbc.m010602200 11278707
Gegelashvili G. Civenni G. Racagni G. Danbolt N. C. Schousboe I. Schousboe A. (1996). Glutamate receptor agonists up-regulate glutamate transporter GLAST in astrocytes. Neuroreport 8 261–265. 10.1097/00001756-199612200-00052 9051792
Gegelashvili G. Schousboe A. (1997). High affinity glutamate transporters: regulation of expression and activity. Mol. Pharmacol. 52 6–15. 10.1124/mol.52.1.6 9224806
Genoud C. Quairiaux C. Steiner P. Hirling H. Welker E. Knott G. W. (2006). Plasticity of astrocytic coverage and glutamate transporter expression in adult mouse cortex. PLoS Biol. 4 :e343 . 10.1371/journal.pbio.0040343 17048987
German C. L. Baladi M. G. McFadden L. M. Hanson G. R. Fleckenstein A. E. (2015). Regulation of the dopamine and vesicular monoamine transporters: pharmacological targets and implications for disease. Pharmacol. Rev. 67 1005–1024. 10.1124/pr.114.010397 26408528
Ginsberg S. D. Martin L. J. Rothstein J. D. (1995). Regional deafferentation down-regulates subtypes of glutamate transporter proteins. J. Neurochem. 65 2800–2803. 10.1046/j.1471-4159.1995.65062800.x 7595581
Goldberg N. R. Beuming T. Soyer O. S. Goldstein R. A. Weinstein H. Javitch J. A. (2003). Probing conformational changes in neurotransmitter transporters: a structural context. Eur. J. Pharmacol. 479 3–12. 10.1016/j.ejphar.2003.08.052 14612133
Goncalves P. P. Carvalho A. P. Vale M. G. (1997). Regulation of [gamma-3H]aminobutyric acid transport by Ca2 + in isolated synaptic plasma membrane vesicles. Brain Res. Mol. Brain Res. 51 106–114. 10.1016/s0169-328x(97)00223-4 9427512
Goncalves P. P. Meireles S. M. Vale M. G. (1999). Regulation of the gamma-aminobutyric acid transporter activity by protein phosphatases in synaptic plasma membranes. Neurosci. Res. 33 41–47. 10.1016/s0168-0102(98)00107-2 10096470
Gonzalez M. I. Kazanietz M. G. Robinson M. B. (2002). Regulation of the neuronal glutamate transporter excitatory amino acid carrier-1 (EAAC1) by different protein kinase C subtypes. Mol. Pharmacol. 62 901–910. 10.1124/mol.62.4.901 12237337
Gonzalez M. I. Lopez-Colom A. M. Ortega A. (1999). Sodium-dependent glutamate transport in Muller glial cells: regulation by phorbol esters. Brain Res. 831 140–145. 10.1016/s0006-8993(99)01438-9 10411993
Gonzalez-Gonzalez I. M. Garcia-Tardon N. Cubelos B. Gimenez C. Zafra F. (2008a). The glutamate transporter GLT1b interacts with the scaffold protein PSD-95. J. Neurochem. 105 1834–1848. 10.1111/j.1471-4159.2008.05281.x 18248606
Gonzalez-Gonzalez I. M. Garcia-Tardon N. Gimenez C. Zafra F. (2008b). PKC-dependent endocytosis of the GLT1 glutamate transporter depends on ubiquitylation of lysines located in a C-terminal cluster. Glia 56 963–974. 10.1002/glia.20670 18381652
Goodspeed K. Pérez-Palma E. Iqbal S. Cooper D. Scimemi A. Johannesen K. M. (2020). Current knowledge of SLC6A1-related neurodevelopmental disorders. Brain Commun. 2 :fcaa170 .
Gorentla B. K. Vaughan R. A. (2005). Differential effects of dopamine and psychoactive drugs on dopamine transporter phosphorylation and regulation. Neuropharmacology 49 759–768. 10.1016/j.neuropharm.2005.08.011 16181646
Gowrishankar R. Hahn M. K. Blakely R. D. (2014). Good riddance to dopamine: roles for the dopamine transporter in synaptic function and dopamine-associated brain disorders. Neurochem. Int. 73 42–48. 10.1016/j.neuint.2013.10.016 24231471
Granas C. Ferrer J. Loland C. J. Javitch J. A. Gether U. (2003). N-terminal truncation of the dopamine transporter abolishes phorbol ester- and substance P receptor-stimulated phosphorylation without impairing transporter internalization. J. Biol. Chem. 278 4990–5000. 10.1074/jbc.m205058200 12464618
Grewer C. Balani P. Weidenfeller C. Bartusel T. Tao Z. Rauen T. (2005). Individual subunits of the glutamate transporter EAAC1 homotrimer function independently of each other. Biochemistry 44 11913–11923. 10.1021/bi050987n 16128593
Grewer C. Madani Mobarekeh S. A. Watzke N. Rauen T. Schaper K. (2001). Substrate translocation kinetics of excitatory amino acid carrier 1 probed with laser-pulse photolysis of a new photolabile precursor of D-aspartic acid. Biochemistry 40 232–240. 10.1021/bi0015919 11141075
Grewer C. Rauen T. (2005). Electrogenic glutamate transporters in the CNS: molecular mechanism, pre-steady-state kinetics, and their impact on synaptic signaling. J. Membr. Biol. 203 1–20. 10.1007/s00232-004-0731-6 15834685
Grewer C. Watzke N. Wiessner M. Rauen T. (2000). Glutamate translocation of the neuronal glutamate transporter EAAC1 occurs within milliseconds. Proc. Natl. Acad. Sci. U.S.A. 97 9706–9711. 10.1073/pnas.160170397 10931942
Gu H. Wall S. C. Rudnick G. (1994). Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics, and ion dependence. J. Biol. Chem. 269 7124–7130. 10.1016/s0021-9258(17)37256-3 8125921
Guillet B. A. Velly L. J. Canolle B. Masmejean F. M. Nieoullon A. L. Pisano P. (2005). Differential regulation by protein kinases of activity and cell surface expression of glutamate transporters in neuron-enriched cultures. Neurochem. Int. 46 337–346. 10.1016/j.neuint.2004.10.006 15707698
Gulley J. M. Doolen S. Zahniser N. R. (2002). Brief, repeated exposure to substrates down-regulates dopamine transporter function in Xenopus oocytes in vitro and rat dorsal striatum in vivo. J. Neurochem. 83 400–411. 10.1046/j.1471-4159.2002.01133.x 12423250
Guskov A. Jensen S. Faustino I. Marrink S. J. Slotboom D. J. (2016). Coupled binding mechanism of three sodium ions and aspartate in the glutamate transporter homologue GltTk. Nat. Commun. 7 :13420 .
Hagiwara T. Tanaka K. Takai S. Maeno-Hikichi Y. Mukainaka Y. Wada K. (1996). Genomic organization, promoter analysis, and chromosomal localization of the gene for the mouse glial high-affinity glutamate transporter Slc1a3. Genomics 33 508–515. 10.1006/geno.1996.0226 8661010
Hancock J. F. (2006). Lipid rafts: contentious only from simplistic standpoints. Nat. Rev. Mol. Cell Biol. 7 456–462. 10.1038/nrm1925 16625153
Hansen F. H. Skjørringe T. Yasmeen S. Arends N. V. Sahai M. A. Erreger K. (2014). Missense dopamine transporter mutations associate with adult parkinsonism and ADHD. J. Clin. Invest. 124 3107–3120. 10.1172/jci73778 24911152
Harsing L. G. Jr. Solyom S. Salamon C. (2001). The role of glycineB binding site and glycine transporter (GlyT1) in the regulation of [3H]GABA and [3H]glycine release in the rat brain. Neurochem. Res. 26 915–923.11699943
Haugeto O. Ullensvang K. Levy L. M. Chaudhry F. A. Honore T. Nielsen M. (1996). Brain glutamate transporter proteins form homomultimers. J. Biol. Chem. 271 27715–27722. 10.1074/jbc.271.44.27715 8910364
Hefendehl J. K. LeDue J. Ko R. W. Mahler J. Murphy T. H. MacVicar B. A. (2016). Mapping synaptic glutamate transporter dysfunction in vivo to regions surrounding Abeta plaques by iGluSnFR two-photon imaging. Nat. Commun. 7 :13441 .
Hepp R. Perraut M. Chasserot-Golaz S. Galli T. Aunis D. Langley K. (1999). Cultured glial cells express the SNAP-25 analogue SNAP-23. Glia 27 181–187. 10.1002/(sici)1098-1136(199908)27:2<181::aid-glia8>3.0.co;2-9 10417817
Herborg F. Andreassen T. F. Berlin F. Loland C. J. Gether U. (2018). Neuropsychiatric disease-associated genetic variants of the dopamine transporter display heterogeneous molecular phenotypes. J. Biol. Chem. 293 , 7250–7262. 10.1074/jbc.RA118.001753 29559554
Herde M. K. Bohmbach K. Domingos C. Vana N. Komorowska-Muller J. A. Passlick S. (2020). Local efficacy of glutamate uptake decreases with synapse size. Cell Rep. 32 :108182 . 10.1016/j.celrep.2020.108182 32966786
Hertz L. Bock E. Schousboe A. (1978). GFA content, glutamate uptake and activity of glutamate metabolizing enzymes in differentiating mouse astrocytes in primary cultures. Dev. Neurosci. 1 226–238. 10.1159/000112577
Heshmati M. Christoffel D. J. LeClair K. Cathomas F. Golden S. A. Aleyasin H. (2020). Depression and social defeat stress are associated with inhibitory synaptic changes in the nucleus accumbens. J. Neurosci. 40 6228–6233. 10.1523/jneurosci.2568-19.2020 32561672
Higuera-Matas A. Miguens M. Coria S. M. Assis M. A. Borcel E. del Olmo N. (2012). Sex-specific disturbances of the glutamate/GABA balance in the hippocampus of adult rats subjected to adolescent cannabinoid exposure. Neuropharmacology 62 1975–1984. 10.1016/j.neuropharm.2011.12.028 22245681
Hoffman A. F. Lupica C. R. Gerhardt G. A. (1998). Dopamine transporter activity in the substantia nigra and striatum assessed by high-speed chronoamperometric recordings in brain slices. J. Pharmacol. Exp. Ther. 287 487–496.9808671
Hofmann K. Duker M. Fink T. Lichter P. Stoffel W. (1994). Human neutral amino acid transporter ASCT1: structure of the gene (SLC1A4) and localization to chromosome 2p13-p15. Genomics 24 20–26. 10.1006/geno.1994.1577 7896285
Holmseth S. Scott H. A. Real K. Lehre K. P. Leergaard T. B. Bjaalie J. G. (2009). The concentrations and distributions of three C-terminal variants of the GLT1 (EAAT2; slc1a2) glutamate transporter protein in rat brain tissue suggest differential regulation. Neuroscience 162 1055–1071. 10.1016/j.neuroscience.2009.03.048 19328838
Holton K. L. Loder M. K. Melikian H. E. (2005). Nonclassical, distinct endocytic signals dictate constitutive and PKC-regulated neurotransmitter transporter internalization. Nat. Neurosci. 8 881–888. 10.1038/nn1478 15924135
Hong W. C. Amara S. G. (2010). Membrane cholesterol modulates the outward facing conformation of the dopamine transporter and alters cocaine binding. J. Biol. Chem. 285 32616–32626. 10.1074/jbc.m110.150565 20688912
Hong W. C. Amara S. G. (2013). Differential targeting of the dopamine transporter to recycling or degradative pathways during amphetamine- or PKC-regulated endocytosis in dopamine neurons. FASEB J. 27 2995–3007. 10.1096/fj.12-218727 23612789
Hoover B. R. Everett C. V. Sorkin A. Zahniser N. R. (2007). Rapid regulation of dopamine transporters by tyrosine kinases in rat neuronal preparations. J. Neurochem. 101 1258–1271. 10.1111/j.1471-4159.2007.04522.x 17419806
Horton N. Quick M. W. (2001). Syntaxin 1A up-regulates GABA transporter expression by subcellular redistribution. Mol. Membr. Biol. 18 39–44. 10.1080/09687680010029383 11396610
Hu J. Fei J. Reutter W. Fan H. (2011). Involvement of sialic acid in the regulation of gamma–aminobutyric acid uptake activity of gamma-aminobutyric acid transporter 1. Glycobiology 21 329–339. 10.1093/glycob/cwq166 21045010
Hu J. Quick M. W. (2008). Substrate-mediated regulation of gamma-aminobutyric acid transporter 1 in rat brain. Neuropharmacology 54 309–318. 10.1016/j.neuropharm.2007.09.013 17991494
Huang H. T. Liao C. K. Chiu W. T. Tzeng S. F. (2017). Ligands of peroxisome proliferator-activated receptor-alpha promote glutamate transporter-1 endocytosis in astrocytes. Int. J. Biochem. Cell Biol. 86 42–53. 10.1016/j.biocel.2017.03.008 28323206
Hudson B. D. Hebert T. E. Kelly M. E. (2010). Physical and functional interaction between CB1 cannabinoid receptors and beta2-adrenoceptors. Br. J. Pharmacol. 160 627–642. 10.1111/j.1476-5381.2010.00681.x 20590567
Huff R. A. Vaughan R. A. Kuhar M. J. Uhl G. R. (1997). Phorbol esters increase dopamine transporter phosphorylation and decrease transport Vmax. J. Neurochem. 68 225–232. 10.1046/j.1471-4159.1997.68010225.x 8978729
Imoukhuede P. I. Moss F. J. Michael D. J. Chow R. H. Lester H. A. (2009). Ezrin mediates tethering of the gamma-aminobutyric acid transporter GAT1 to actin filaments via a C-terminal PDZ-interacting domain. Biophys. J. 96 2949–2960. 10.1016/j.bpj.2008.11.070 19348776
Ingram S. L. Prasad B. M. Amara S. G. (2002). Dopamine transporter-mediated conductances increase excitability of midbrain dopamine neurons. Nat. Neurosci. 5 971–978. 10.1038/nn920 12352983
Jacob C. P. Koutsilieri E. Bartl J. Neuen-Jacob E. Arzberger T. Zander N. (2007). Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer’s disease. J. Alzheimers Dis. 11 97–116. 10.3233/jad-2007-11113 17361039
Jansson L. C. Louhivuori L. Wigren H. K. Nordstrom T. Louhivuori V. Castren M. L. (2013). Effect of glutamate receptor antagonists on migrating neural progenitor cells. Eur. J. Neurosci. 37 1369–1382. 10.1111/ejn.12152 23383979
Jayanthi L. D. Vargas G. DeFelice L. J. (2002). Characterization of cocaine and antidepressant-sensitive norepinephrine transporters in rat placental trophoblasts. Br. J. Pharmacol. 135 1927–1934. 10.1038/sj.bjp.0704658 11959795
Ji Y. F. Xu S. M. Zhu J. Wang X. X. Shen Y. (2011). Insulin increases glutamate transporter GLT1 in cultured astrocytes. Biochem. Biophys. Res. Commun. 405 691–696. 10.1016/j.bbrc.2011.01.105 21291866
Ji Y. F. Zhou L. Xie Y. J. Xu S. M. Zhu J. Teng P. (2013). Upregulation of glutamate transporter GLT-1 by mTOR-Akt-NF-small ka, CyrillicB cascade in astrocytic oxygen-glucose deprivation. Glia 61 1959–1975. 10.1002/glia.22566 24108520
Jiang N. W. Wang D. J. Xie Y. J. Zhou L. Su L. D. Li H. (2016). Downregulation of glutamate transporter EAAT4 by conditional knockout of rheb1 in Cerebellar Purkinje cells. Cerebellum 15 314–321. 10.1007/s12311-015-0701-9 26194056
Johnson L. A. Furman C. A. Zhang M. Guptaroy B. Gnegy M. E. (2005a). Rapid delivery of the dopamine transporter to the plasmalemmal membrane upon amphetamine stimulation. Neuropharmacology 49 750–758. 10.1016/j.neuropharm.2005.08.018 16212991
Johnson L. A. Guptaroy B. Lund D. Shamban S. Gnegy M. E. (2005b). Regulation of amphetamine-stimulated dopamine efflux by protein kinase C beta. J. Biol. Chem. 280 10914–10919. 10.1074/jbc.m413887200 15647254
Jones K. T. Zhen J. Reith M. E. (2012). Importance of cholesterol in dopamine transporter function. J. Neurochem. 123 700–715. 10.1111/jnc.12007 22957537
Jones S. R. Gainetdinov R. R. Wightman R. M. Caron M. G. (1998). Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J. Neurosci. 18 1979–1986. 10.1523/jneurosci.18-06-01979.1998 9482784
Jones S. R. Joseph J. D. Barak L. S. Caron M. G. Wightman R. M. (1999). Dopamine neuronal transport kinetics and effects of amphetamine. J. Neurochem. 73 2406–2414. 10.1046/j.1471-4159.1999.0732406.x 10582600
Kahlig K. M. Binda F. Khoshbouei H. Blakely R. D. McMahon D. G. Javitch J. A. (2005). Amphetamine induces dopamine efflux through a dopamine transporter channel. Proc. Natl. Acad. Sci. U.S.A. 102 3495–3500. 10.1073/pnas.0407737102 15728379
Kahlig K. M. Galli A. (2003). Regulation of dopamine transporter function and plasma membrane expression by dopamine, amphetamine, and cocaine. Eur. J. Pharmacol. 479 153–158. 10.1016/j.ejphar.2003.08.065 14612146
Kahlig K. M. Javitch J. A. Galli A. (2004). Amphetamine regulation of dopamine transport. Combined measurements of transporter currents and transporter imaging support the endocytosis of an active carrier. J. Biol. Chem. 279 8966–8975.14699142
Kalandadze A. Wu Y. Robinson M. B. (2002). Protein kinase C activation decreases cell surface expression of the GLT-1 subtype of glutamate transporter. Requirement of a carboxyl-terminal domain and partial dependence on serine 486. J. Biol. Chem. 277 45741–45750. 10.1074/jbc.m203771200 12324450
Kang M. Ryu J. Kim J. H. Na H. Zuo Z. Do S. H. (2010). Corticosterone decreases the activity of rat glutamate transporter type 3 expressed in Xenopus oocytes. Steroids 75 1113–1118. 10.1016/j.steroids.2010.07.003 20654639
Kanner B. I. (2003). Transmembrane domain I of the gamma-aminobutyric acid transporter GAT-1 plays a crucial role in the transition between cation leak and transport modes. J. Biol. Chem. 278 3705–3712. 10.1074/jbc.m210525200 12446715
Karam C. S. Javitch J. A. (2018). Phosphorylation of the amino terminus of the dopamine transporter: regulatory mechanisms and implications for amphetamine action. Adv. Pharmacol. 82 205–234. 10.1016/bs.apha.2017.09.002 29413521
Karatas-Wulf U. Koepsell H. Bergert M. Sonnekes S. Kugler P. (2009). Protein kinase C-dependent trafficking of glutamate transporters excitatory amino acid carrier 1 and glutamate transporter 1b in cultured cerebellar granule cells. Neuroscience 161 794–805. 10.1016/j.neuroscience.2009.04.017 19364521
Karki P. Webb A. Smith K. Johnson J. Jr. Lee K. Son D. S. (2014). Yin Yang 1 is a repressor of glutamate transporter EAAT2, and it mediates manganese-induced decrease of EAAT2 expression in astrocytes. Mol. Cell Biol. 34 1280–1289. 10.1128/mcb.01176-13 24469401
Karylowski O. Zeigerer A. Cohen A. McGraw T. E. (2004). GLUT4 is retained by an intracellular cycle of vesicle formation and fusion with endosomes. Mol. Biol. Cell 15 870–882. 10.1091/mbc.e03-07-0517 14595108
Kerkerian L. Dusticier N. Nieoullon A. (1987). Modulatory effect of dopamine on high-affinity glutamate uptake in the rat striatum. J. Neurochem. 48 1301–1306. 10.1111/j.1471-4159.1987.tb05661.x 2880932
Keynan S. Kanner B. I. (1988). gamma-Aminobutyric acid transport in reconstituted preparations from rat brain: coupled sodium and chloride fluxes. Biochemistry 27 12–17. 10.1021/bi00401a003 3349023
Khoshbouei H. Sen N. Guptaroy B. Johnson L. Lund D. Gnegy M. E. (2004). N-terminal phosphorylation of the dopamine transporter is required for amphetamine-induced efflux. PLoS Biol. 2 :E78 . 10.1371/journal.pbio.0020078 15024426
Kilty J. E. Lorang D. Amara S. G. (1991). Cloning and expression of a cocaine-sensitive rat dopamine transporter. Science 254 578–579. 10.1126/science.1948035 1948035
Kim D. U. Kim M. K. Cho Y. W. Kim Y. S. Kim W. J. Lee M. G. (2011). Association of a synonymous GAT3 polymorphism with antiepileptic drug pharmacoresistance. J. Hum. Genet. 56 640–646. 10.1038/jhg.2011.73 21776001
Kim S. Westphalen R. Callahan B. Hatzidimitriou G. Yuan J. Ricaurte G. A. (2000). Toward development of an in vitro model of methamphetamine-induced dopamine nerve terminal toxicity. J. Pharmacol. Exp. Ther. 293 625–633.10773037
Kimmel H. L. Carroll F. I. Kuhar M. J. (2000). Dopamine transporter synthesis and degradation rate in rat striatum and nucleus accumbens using RTI-76. Neuropharmacology 39 578–585. 10.1016/s0028-3908(99)00160-4 10728879
Kinney G. A. (2005). GAT-3 transporters regulate inhibition in the neocortex. J, Neurophysiol. 94 4533–4537. 10.1152/jn.00420.2005 16135550
Kitayama S. Dohi T. Uhl G. R. (1994). Phorbol esters alter functions of the expressed dopamine transporter. Eur. J. Pharmacol. 268 115–119. 10.1016/0922-4106(94)90180-5 7957633
Kivell B. Uzelac Z. Sundaramurthy S. Rajamanickam J. Ewald A. Chefer V. (2014). Salvinorin A regulates dopamine transporter function via a kappa opioid receptor and ERK1/2-dependent mechanism. Neuropharmacology 86 228–240. 10.1016/j.neuropharm.2014.07.016 25107591
Koch H. P. Brown R. L. Larsson H. P. (2007). The glutamate-activated anion conductance in excitatory amino acid transporters is gated independently by the individual subunits. J. Neurosci. 27 2943–2947. 10.1523/jneurosci.0118-07.2007 17360917
Kolen B. Kortzak D. Franzen A. Fahlke C. (2020). An amino-terminal point mutation increases EAAT2 anion currents without affecting glutamate transport rates. J. Biol. Chem. 295 14936–14947. 10.1074/jbc.ra120.013704 32820048
Kovtun O. Sakrikar D. Tomlinson I. D. Chang J. C. Arzeta-Ferrer X. Blakely R. D. (2015). Single-quantum-dot tracking reveals altered membrane dynamics of an attention-deficit/hyperactivity-disorder-derived dopamine transporter coding variant. ACS Chem. Neurosci. 6 526–534. 10.1021/cn500202c 25747272
Kristensen A. S. Andersen J. Jorgensen T. N. Sorensen L. Eriksen J. Loland C. J. (2011). SLC6 neurotransmitter transporters: structure, function, and regulation. Pharmacol. Rev. 63 585–640.21752877
Krueger B. K. (1990). Kinetics and block of dopamine uptake in synaptosomes from rat caudate nucleus. J. Neurochem. 55 260–267. 10.1111/j.1471-4159.1990.tb08847.x 2355221
Laughlin T. M. Tram K. V. Wilcox G. L. Birnbaum A. K. (2002). Comparison of antiepileptic drugs tiagabine, lamotrigine, and gabapentin in mouse models of acute, prolonged, and chronic nociception. J. Pharmacol. Exp. Ther. 302 1168–1175. 10.1124/jpet.302.3.1168 12183677
Law R. M. Stafford A. Quick M. W. (2000). Functional regulation of gamma-aminobutyric acid transporters by direct tyrosine phosphorylation. J. Biol. Chem. 275 23986–23991. 10.1074/jbc.m910283199 10816599
Leary G. P. Holley D. C. Stone E. F. Lyda B. R. Kalachev L. V. Kavanaugh M. P. (2011). The central cavity in trimeric glutamate transporters restricts ligand diffusion. Proc. Natl. Acad. Sci. U.S.A. 108 14980–14985. 10.1073/pnas.1108785108 21873219
Leary G. P. Stone E. F. Holley D. C. Kavanaugh M. P. (2007). The glutamate and chloride permeation pathways are colocalized in individual neuronal glutamate transporter subunits. J. Neurosci. 27 2938–2942. 10.1523/jneurosci.4851-06.2007 17360916
Lee F. J. Liu F. Pristupa Z. B. Niznik H. B. (2001). Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J. 15 916–926. 10.1096/fsb2fj000334com 11292651
Lee F. J. Pei L. Moszczynska A. Vukusic B. Fletcher P. J. Liu F. (2007). Dopamine transporter cell surface localization facilitated by a direct interaction with the dopamine D2 receptor. EMBO J. 26 2127–2136. 10.1038/sj.emboj.7601656 17380124
Lee G. Huang Y. Washington J. M. Briggs N. W. Zuo Z. (2005). Carbamazepine enhances the activity of glutamate transporter type 3 via phosphatidylinositol 3-kinase. Epilepsy Res. 66 145–153. 10.1016/j.eplepsyres.2005.08.003 16150575
Lee H. S. Bae E. J. Yi S. H. Shim J. W. Jo A. Y. Kang J. S. (2010). Foxa2 and Nurr1 synergistically yield A9 nigral dopamine neurons exhibiting improved differentiation, function, and cell survival. Stem Cells 28 501–512.20049900
Lee K. H. Kim M. Y. Kim D. H. Lee Y. S. (2004). Syntaxin 1A and receptor for activated C kinase interact with the N-terminal region of human dopamine transporter. Neurochem. Res. 29 1405–1409. 10.1023/b:nere.0000026404.08779.43 15202772
Lehre K. P. Danbolt N. C. (1998). The number of glutamate transporter subtype molecules at glutamatergic synapses: chemical and stereological quantification in young adult rat brain. J. Neurosci. 18 8751–8757. 10.1523/jneurosci.18-21-08751.1998 9786982
Lehre K. P. Levy L. M. Ottersen O. P. Storm-Mathisen J. Danbolt N. C. (1995). Differential expression of two glial glutamate transporters in the rat brain: quantitative and immunocytochemical observations. J. Neurosci. 15 1835–1853. 10.1523/jneurosci.15-03-01835.1995 7891138
Leng K. Li E. Eser R. Piergies A. Sit R. Tan M. (2021). Molecular characterization of selectively vulnerable neurons in Alzheimer’s disease. Nat. Neurosci. 24 276–287.33432193
Leonova J. Thorlin T. Aberg N. D. Eriksson P. S. Ronnback L. Hansson E. (2001). Endothelin-1 decreases glutamate uptake in primary cultured rat astrocytes. Am. J. Physiol. Cell Physiol. 281 C1495–C1503.11600412
Levy L. Lehre K. Walaas S. Storm-Mathisen J. Danbolt N. (1995). Down-regulation of glial glutamate transporters after glutamatergic denervation in the rat brain. Eur. J. Neurosci. 7 2036–2041. 10.1111/j.1460-9568.1995.tb00626.x 8542061
Levy L. M. Lehre K. P. Rolstad B. Danbolt N. C. (1993). A monoclonal antibody raised against an [Na(+)+K+]coupled L-glutamate transporter purified from rat brain confirms glial cell localization. FEBS Lett. 317 79–84. 10.1016/0014-5793(93)81495-l 7679083
Levy L. M. Warr O. Attwell D. (1998). Stoichiometry of the glial glutamate transporter GLT-1 expressed inducibly in a Chinese hamster ovary cell line selected for low endogenous Na+-dependent glutamate uptake. J. Neurosci. 18 9620–9628. 10.1523/jneurosci.18-23-09620.1998 9822723
Li L. B. Toan S. V. Zelenaia O. Watson D. J. Wolfe J. H. Rothstein J. D. (2006). Regulation of astrocytic glutamate transporter expression by Akt: evidence for a selective transcriptional effect on the GLT-1/EAAT2 subtype. J. Neurochem. 97 759–771. 10.1111/j.1471-4159.2006.03743.x 16573655
Li M. H. Underhill S. M. Reed C. Phillips T. J. Amara S. G. Ingram S. L. (2017). Amphetamine and methamphetamine increase NMDAR-GluN2B synaptic currents in midbrain dopamine neurons. Neuropsychopharmacology 42 1539–1547. 10.1038/npp.2016.278 27976681
Li S. Mallory M. Alford M. Tanaka S. Masliah E. (1997). Glutamate transporter alterations in Alzheimer disease are possibly associated with abnormal APP expression. J. Neuropathol. Exp. Neurol. 56 901–911. 10.1097/00005072-199708000-00008 9258260
Lim S. K. Park M. J. Jung H. K. Park A. Y. Kim D. I. Kim J. C. (2008). Bradykinin stimulates glutamate uptake via both B1R and B2R activation in a human retinal pigment epithelial cells. Life Sci. 83 761–770. 10.1016/j.lfs.2008.09.014 18948121
Lin C. L. Tzingounis A. V. Jin L. Furuta A. Kavanaugh M. P. Rothstein J. D. (1998). Molecular cloning and expression of the rat EAAT4 glutamate transporter subtype. Brain Res. Mol. Brain Res. 63 174–179. 10.1016/s0169-328x(98)00256-3 9838098
Loder M. K. Melikian H. E. (2003). The dopamine transporter constitutively internalizes and recycles in a protein kinase C-regulated manner in stably transfected PC12 cell lines. J. Biol. Chem. 278 22168–22174. 10.1074/jbc.m301845200 12682063
Lu C.-C. Hilgemann D. W. (1999). GAT1 (GABA: Na+: Cl–) cotransport function: steady state studies in giant Xenopus oocyte membrane patches. J. Gen. Physiol. 114 429–444. 10.1085/jgp.114.3.429 10469733
Lushnikova I. Skibo G. Muller D. Nikonenko I. (2009). Synaptic potentiation induces increased glial coverage of excitatory synapses in CA1 hippocampus. Hippocampus 19 753–762. 10.1002/hipo.20551 19156853
Lute B. J. Khoshbouei H. Saunders C. Sen N. Lin R. Z. Javitch J. A. (2008). PI3K signaling supports amphetamine-induced dopamine efflux. Biochem. Biophys. Res. Commun. 372 656–661. 10.1016/j.bbrc.2008.05.091 18510945
MacAulay N. Zeuthen T. Gether U. (2002). Conformational basis for the Li(+)-induced leak current in the rat gamma-aminobutyric acid (GABA) transporter-1. J. Physiol. 544 447–458. 10.1113/jphysiol.2002.022897 12381817
Mager S. Min C. Henry D. J. Chavkin C. Hoffman B. J. Davidson N. (1994). Conducting states of a mammalian serotonin transporter. Neuron 12 845–859. 10.1016/0896-6273(94)90337-9 8161456
Mager S. Naeve J. Quick M. Labarca C. Davidson N. Lester H. A. (1993). Steady states, charge movements, and rates for a cloned GABA transporter expressed in Xenopus oocytes. Neuron 10 177–188. 10.1016/0896-6273(93)90309-f 7679914
Malik A. R. Willnow T. E. (2019). Excitatory amino acid transporters in physiology and disorders of the central nervous system. Int. J. Mol. Sci. 20 :5671 . 10.3390/ijms20225671 31726793
Maragakis N. J. Dykes-Hoberg M. Rothstein J. D. (2004). Altered expression of the glutamate transporter EAAT2b in neurological disease. Ann. Neurol. 55 469–477. 10.1002/ana.20003 15048885
Martinez-Lozada Z. Guillem A. M. Robinson M. B. (2016). Transcriptional regulation of glutamate transporters: from extracellular signals to transcription factors. Adv. Pharmacol. 76 103–145.27288076
Martins R. S. de Freitas I. G. Sathler M. F. Martins V. Schitine C. S. da Silva Sampaio L. (2018). Beta-adrenergic receptor activation increases GABA uptake in adolescent mice frontal cortex: Modulation by cannabinoid receptor agonist WIN55,212-2. Neurochem. Int. 120 182–190. 10.1016/j.neuint.2018.08.011 30170018
Mason J. N. Farmer H. Tomlinson I. D. Schwartz J. W. Savchenko V. DeFelice L. J. (2005). Novel fluorescence-based approaches for the study of biogenic amine transporter localization, activity, and regulation. J. Neurosci. Methods 143 3–25. 10.1016/j.jneumeth.2004.09.028 15763132
Matsusaki M. Kishida A. Stainton N. Ansell C. W. G. Akashi M. (2001). Synthesis and characterization of novel biodegradable polymers composed of hydroxycinnamic acid and D,L-lactic acid. J. Appl. Polym. Sci. 82 2357–2364. 10.1002/app.2085
Matthews E. Jr. Rahnama-Vaghef A. Eskandari S. (2009). Inhibitors of the γ-aminobutyric acid transporter 1 (GAT1) do not reveal a channel mode of conduction. Neurochem. Intern. 55 732–740. 10.1016/j.neuint.2009.07.005 19622377
Mazei-Robison M. S. Couch R. S. Shelton R. C. Stein M. A. Blakely R. D. (2005). Sequence variation in the human dopamine transporter gene in children with attention deficit hyperactivity disorder. Neuropharmacology 49 724–736. 10.1016/j.neuropharm.2005.08.003 16171832
McElvain J. S. Schenk J. O. (1992). A multisubstrate mechanism of striatal dopamine uptake and its inhibition by cocaine. Biochem. Pharmacol. 43 2189–2199. 10.1016/0006-2952(92)90178-l 1599505
McGeer P. McGeer E. Scherer U. Singh K. (1977). A glutamatergic corticostriatal path? Brain Res. 128 369–373. 10.1016/0006-8993(77)91003-4 871919
McHugh E. M. Zhu W. Milgram S. Mager S. (2004). The GABA transporter GAT1 and the MAGUK protein Pals1: interaction, uptake modulation, and coexpression in the brain. Mol. Cell Neurosci. 26 406–417. 10.1016/j.mcn.2004.03.006 15234345
McNair L. F. Andersen J. V. Aldana B. I. Hohnholt M. C. Nissen J. D. Sun Y. (2019). Deletion of neuronal GLT-1 in mice reveals its role in synaptic glutamate homeostasis and mitochondrial function. J. Neurosci. 39 4847–4863. 10.1523/jneurosci.0894-18.2019 30926746
McNair L. F. Andersen J. V. Nissen J. D. Sun Y. Fischer K. D. Hodgson N. W. (2020). Conditional knockout of GLT-1 in neurons leads to alterations in aspartate homeostasis and synaptic mitochondrial metabolism in Striatum and Hippocampus. Neurochem. Res. 45 1420–1437. 10.1007/s11064-020-03000-7 32144526
Medvedev N. Popov V. Henneberger C. Kraev I. Rusakov D. A. Stewart M. G. (2014). Glia selectively approach synapses on thin dendritic spines. Philos. Trans. R. Soc. Lond. B Biol. Sci. 369 :20140047 . 10.1098/rstb.2014.0047 25225105
Melikian H. E. Buckley K. M. (1999). Membrane trafficking regulates the activity of the human dopamine transporter. J. Neurosci. 19 7699–7710. 10.1523/jneurosci.19-18-07699.1999 10479674
Melone M. Barbaresi P. Fattorini G. Conti F. (2005). Neuronal localization of the GABA transporter GAT-3 in human cerebral cortex: a procedural artifact? J. Chem. Neuroanat. 30 45–54. 10.1016/j.jchemneu.2005.04.002 15923108
Melone M. Bellesi M. Conti F. (2009). Synaptic localization of GLT-1a in the rat somatic sensory cortex. Glia 57 108–117. 10.1002/glia.20744 18720407
Melone M. Bellesi M. Ducati A. Iacoangeli M. Conti F. (2011). Cellular and synaptic localization of EAAT2a in human cerebral cortex. Front. Neuroanat. 4 :151 . 10.3389/fnana.2010.00151 21258616
Melone M. Ciappelloni S. Conti F. (2015). A quantitative analysis of cellular and synaptic localization of GAT-1 and GAT-3 in rat neocortex. Brain Struct. Funct. 220 885–897. 10.1007/s00429-013-0690-8 24368619
Melone M. Ciriachi C. Pietrobon D. Conti F. (2019). Heterogeneity of Astrocytic and neuronal GLT-1 at cortical excitatory synapses, as revealed by its colocalization with Na+/K+-ATPase alpha isoforms. Cereb. Cortex 29 3331–3350. 10.1093/cercor/bhy203 30260367
Melone M. Cozzi A. Pellegrini-Giampietro D. E. Conti F. (2003). Transient focal ischemia triggers neuronal expression of GAT-3 in the rat perilesional cortex. Neurobiol. Dis. 14 120–132. 10.1016/s0969-9961(03)00042-1 13678673
Mergy M. A. Gowrishankar R. Davis G. L. Jessen T. N. Wright J. Stanwood G. D. (2014). Genetic targeting of the amphetamine and methylphenidate-sensitive dopamine transporter: on the path to an animal model of attention-deficit hyperactivity disorder. Neurochem. Int. 73 56–70. 10.1016/j.neuint.2013.11.009 24332984
Metzger R. R. Haughey H. M. Wilkins D. G. Gibb J. W. Hanson G. R. Fleckenstein A. E. (2000). Methamphetamine-induced rapid decrease in dopamine transporter function: role of dopamine and hyperthermia. J. Pharmacol. Exp. Ther. 295 1077–1085.11082443
Meyer T. Speer A. Meyer B. Sitte W. Kuther G. Ludolph A. C. (1996). The glial glutamate transporter complementary DNA in patients with amyotrophic lateral sclerosis. Ann. Neurol. 40 456–459. 10.1002/ana.410400317 8797537
Michaluk P. H. Heller J. Rusakov D. A. (2020). Rapid recycling of glutamate transporters on the astroglial surface. bioRxiv [Preprint], 10.1101/2020.11.08.373233v1
Mick E. Faraone S. V. (2009). Family and genetic association studies of bipolar disorder in children. Child Adolesc. Psychiatr. Clin. N. Am. 18 441–453. 10.1016/j.chc.2008.11.008 19264272
Mim C. Balani P. Rauen T. Grewer C. (2005). The glutamate transporter subtypes EAAT4 and EAATs 1-3 transport glutamate with dramatically different kinetics and voltage dependence but share a common uptake mechanism. J. Gen. Physiol. 126 571–589. 10.1085/jgp.200509365 16316976
Minelli A. Barbaresi P. Reimer R. J. Edwards R. H. Conti F. (2001). The glial glutamate transporter GLT-1 is localized both in the vicinity of and at distance from axon terminals in the rat cerebral cortex. Neuroscience 108 51–59. 10.1016/s0306-4522(01)00375-x 11738130
Miranda M. Dionne K. R. Sorkina T. Sorkin A. (2007). Three ubiquitin conjugation sites in the amino terminus of the dopamine transporter mediate protein kinase C-dependent endocytosis of the transporter. Mol. Biol. Cell 18 313–323. 10.1091/mbc.e06-08-0704 17079728
Mitrovic A. D. Plesko F. Vandenberg R. J. (2001). Zn(2+) inhibits the anion conductance of the glutamate transporter EEAT4. J. Biol. Chem. 276 26071–26076. 10.1074/jbc.m011318200 11352900
Mookherjee P. Green P. S. Watson G. S. Marques M. A. Tanaka K. Meeker K. D. (2011). GLT-1 loss accelerates cognitive deficit onset in an Alzheimer’s disease animal model. J. Alzheimers Dis. 26 447–455. 10.3233/jad-2011-110503 21677376
Moritz A. E. Foster J. D. Gorentla B. K. Mazei-Robison M. S. Yang J. W. Sitte H. H. (2013). Phosphorylation of dopamine transporter serine 7 modulates cocaine analog binding. J. Biol. Chem. 288 20–32. 10.1074/jbc.m112.407874 23161550
Moron J. A. Zakharova I. Ferrer J. V. Merrill G. A. Hope B. Lafer E. M. (2003). Mitogen-activated protein kinase regulates dopamine transporter surface expression and dopamine transport capacity. J. Neurosci. 23 8480–8488. 10.1523/jneurosci.23-24-08480.2003 13679416
Moss F. J. Imoukhuede P. I. Scott K. Hu J. Jankowsky J. L. Quick M. W. (2009). GABA transporter function, oligomerization state, and anchoring: correlates with subcellularly resolved FRET. J. Gen. Physiol. 134 489–521. 10.1085/jgp.200910314 19948998
Moszczynska A. Saleh J. Zhang H. Vukusic B. Lee F. J. Liu F. (2007). Parkin disrupts the alpha-synuclein/dopamine transporter interaction: consequences toward dopamine-induced toxicity. J. Mol. Neurosci. 32 217–227. 10.1007/s12031-007-0037-0 17873367
Mukainaka Y. Tanaka K. Hagiwara T. Wada K. (1995). Molecular cloning of two glutamate transporter subtypes from mouse brain. Biochim. Biophys. Acta 1244 233–237. 10.1016/0304-4165(95)00062-g 7766664
Mundorf M. L. Hochstetler S. E. Wightman R. M. (1999). Amine weak bases disrupt vesicular storage and promote exocytosis in chromaffin cells. J. Neurochem. 73 2397–2405. 10.1046/j.1471-4159.1999.0732397.x 10582599
Murphy-Royal C. Dupuis J. P. Varela J. A. Panatier A. Pinson B. Baufreton J. (2015). Surface diffusion of astrocytic glutamate transporters shapes synaptic transmission. Nat. Neurosci. 18 219–226. 10.1038/nn.3901 25581361
Nakayama T. Kawakami H. Tanaka K. Nakamura S. (1996). Expression of three glutamate transporter subtype mRNAs in human brain regions and peripheral tissues. Brain Res. Mol. Brain Res. 36 189–192. 10.1016/0169-328x(95)00297-6 9011758
Navaroli D. M. Stevens Z. H. Uzelac Z. Gabriel L. King M. J. Lifshitz L. M. (2011). The plasma membrane-associated GTPase Rin interacts with the dopamine transporter and is required for protein kinase C-regulated dopamine transporter trafficking. J. Neurosci. 31 13758–13770. 10.1523/jneurosci.2649-11.2011 21957239
Nirenberg M. J. Chan J. Pohorille A. Vaughan R. A. Uhl G. R. Kuhar M. J. (1997). The dopamine transporter: comparative ultrastructure of dopaminergic axons in limbic and motor compartments of the nucleus accumbens. J. Neurosci. 17 6899–6907. 10.1523/jneurosci.17-18-06899.1997 9278525
Norregaard L. Gether U. (2001). The monoamine neurotransmitter transporters: structure, conformational changes and molecular gating. Curr. Opin. Drug Discov. Dev. 4 591–601.
O’Donovan S. M. Sullivan C. R. McCullumsmith R. E. (2017). The role of glutamate transporters in the pathophysiology of neuropsychiatric disorders. NPJ Schizophr. 3 :32 .
Otis T. S. Kavanaugh M. P. (2000). Isolation of current components and partial reaction cycles in the glial glutamate transporter EAAT2. J. Neurosci. 20 2749–2757. 10.1523/jneurosci.20-08-02749.2000 10751425
Padovano V. Massari S. Mazzucchelli S. Pietrini G. (2009). PKC induces internalization and retention of the EAAC1 glutamate transporter in recycling endosomes of MDCK cells. Am. J. Physiol. Cell Physiol. 297 C835–C844.19605734
Page G. Barc-Pain S. Pontcharraud R. Cante A. Piriou A. Barrier L. (2004). The up-regulation of the striatal dopamine transporter’s activity by cAMP is PKA-, CaMK II- and phosphatase-dependent. Neurochem. Int. 45 627–632. 10.1016/j.neuint.2004.04.002 15234104
Pakulska W. (2007). Influence of tiagabine on the antinociceptive action of morphine, metamizole and indomethacin in mice. Acta Pol. Pharm. 64 263–270.17695150
Palos T. P. Ramachandran B. Boado R. Howard B. D. (1996). Rat C6 and human astrocytic tumor cells express a neuronal type of glutamate transporter. Brain Res. Mol. Brain Res. 37 297–303. 10.1016/0169-328x(95)00331-l 8738164
Parinejad N. Peco E. Ferreira T. Stacey S. M. van Meyel D. J. (2016). Disruption of an EAAT-mediated chloride channel in a Drosophila model of Ataxia. J. Neurosci. 36 7640–7647. 10.1523/jneurosci.0197-16.2016 27445142
Park H. Y. Kim J. H. Zuo Z. Do S. H. (2008). Ethanol increases the activity of rat excitatory amino acid transporter type 4 expressed in Xenopus oocytes: role of protein kinase C and phosphatidylinositol 3-kinase. Alcohol. Clin. Exp. Res. 32 348–354. 10.1111/j.1530-0277.2007.00577.x 18226120
Park S. J. Shin H. J. Gu B. W. Woo K. I. Zuo Z. Do S. H. (2015). Desflurane increased the activity of excitatory amino-acid carrier 1 (EAAC1) expressed in Xenopus oocytes. Eur. J. Pharmacol. 757 84–89. 10.1016/j.ejphar.2015.03.058 25840279
Parker E. M. Cubeddu L. X. (1988). Comparative effects of amphetamine, phenylethylamine and related drugs on dopamine efflux, dopamine uptake and mazindol binding. J. Pharmacol. Exp. Ther. 245 199–210.3129549
Parpura V. Fang Y. Basarsky T. Jahn R. Haydon P. G. (1995). Expression of synaptobrevin II, cellubrevin and syntaxin but not SNAP-25 in cultured astrocytes. FEBS Lett. 377 489–492. 10.1016/0014-5793(95)01401-2 8549782
Patrushev I. Gavrilov N. Turlapov V. Semyanov A. (2013). Subcellular location of astrocytic calcium stores favors extrasynaptic neuron-astrocyte communication. Cell Calc. 54 343–349. 10.1016/j.ceca.2013.08.003 24035346
Peacey E. Miller C. C. Dunlop J. Rattray M. (2009). The four major N- and C-terminal splice variants of the excitatory amino acid transporter GLT-1 form cell surface homomeric and heteromeric assemblies. Mol. Pharmacol. 75 1062–1073. 10.1124/mol.108.052829 19201818
Peghini P. Janzen J. Stoffel W. (1997). Glutamate transporter EAAC-1-deficient mice develop dicarboxylic aminoaciduria and behavioral abnormalities but no neurodegeneration. EMBO J. 16 3822–3832. 10.1093/emboj/16.13.3822 9233792
Penmatsa A. Wang K. H. Gouaux E. (2013). X-ray structure of dopamine transporter elucidates antidepressant mechanism. Nature 503 85–90. 10.1038/nature12533 24037379
Penmatsa A. Wang K. H. Gouaux E. (2015). X-ray structures of Drosophila dopamine transporter in complex with Nisoxetine and Reboxetine. Nat. Struct. Mol. Biol. 22 506–508. 10.1038/nsmb.3029 25961798
Perego C. Di Cairano E. S. Ballabio M. Magnaghi V. (2012). Neurosteroid allopregnanolone regulates EAAC1-mediated glutamate uptake and triggers actin changes in Schwann cells. J. Cell Physiol. 227 1740–1751. 10.1002/jcp.22898 21688266
Perez-Alvarez A. Navarrete M. Covelo A. Martin E. D. Araque A. (2014). Structural and functional plasticity of astrocyte processes and dendritic spine interactions. J. Neurosci. 34 12738–12744. 10.1523/jneurosci.2401-14.2014 25232111
Petr G. T. Sun Y. Frederick N. M. Zhou Y. Dhamne S. C. Hameed M. Q. (2015). Conditional deletion of the glutamate transporter GLT-1 reveals that astrocytic GLT-1 protects against fatal epilepsy while neuronal GLT-1 contributes significantly to glutamate uptake into synaptosomes. J. Neurosci. 35 5187–5201. 10.1523/jneurosci.4255-14.2015 25834045
Piani D. Frei K. Pfister H. W. Fontana A. (1993). Glutamate uptake by astrocytes is inhibited by reactive oxygen intermediates but not by other macrophage-derived molecules including cytokines, leukotrienes or platelet-activating factor. J. Neuroimmunol. 48 99–104. 10.1016/0165-5728(93)90063-5 7901235
Picaud S. Larsson H. P. Wellis D. P. Lecar H. Werblin F. (1995). Cone photoreceptors respond to their own glutamate release in the tiger salamander. Proc. Natl. Acad. Sci. U.S.A. 92 9417–9421. 10.1073/pnas.92.20.9417 7568144
Pines G. Danbolt N. C. Bjoras M. Zhang Y. Bendahan A. Eide L. (1992). Cloning and expression of a rat brain L-glutamate transporter. Nature 360 464–467.1448170
Plachez C. Danbolt N. C. Recasens M. (2000). Transient expression of the glial glutamate transporters GLAST and GLT in hippocampal neurons in primary culture. J. Neurosci. Res. 59 587–593. 10.1002/(sici)1097-4547(20000301)59:5<587::aid-jnr1>3.0.co;2-l 10686586
Pogun S. Dawson V. Kuhar M. J. (1994). Nitric oxide inhibits 3H-glutamate transport in synaptosomes. Synapse 18 21–26. 10.1002/syn.890180104 7825120
Pogun S. Kuhar M. J. (1994). Regulation of neurotransmitter reuptake by nitric oxide. Ann. N.Y. Acad. Sci. 738 305–315. 10.1111/j.1749-6632.1994.tb21816.x 7832440
Porton B. Greenberg B. D. Askland K. Serra L. M. Gesmonde J. Rudnick G. (2013). Isoforms of the neuronal glutamate transporter gene, SLC1A1/EAAC1, negatively modulate glutamate uptake: relevance to obsessive-compulsive disorder. Transl. Psychiatry 3 :e259 . 10.1038/tp.2013.35 23695234
Pristupa Z. B. McConkey F. Liu F. Man H. Y. Lee F. J. Wang Y. T. (1998). Protein kinase-mediated bidirectional trafficking and functional regulation of the human dopamine transporter. Synapse 30 79–87. 10.1002/(sici)1098-2396(199809)30:1<79::aid-syn10>3.0.co;2-k 9704884
Quick M. W. Corey J. L. Davidson N. Lester H. A. (1997). Second messengers, trafficking-related proteins, and amino acid residues that contribute to the functional regulation of the rat brain GABA transporter GAT1. J. Neurosci. 17 2967–2979. 10.1523/jneurosci.17-09-02967.1997 9096133
Radian R. Kanner B. I. (1983). Stoichiometry of sodium- and chloride-coupled gamma-aminobutyric acid transport by synaptic plasma membrane vesicles isolated from rat brain. Biochemistry 22 1236–1241. 10.1021/bi00274a038 6838850
Raiteri L. Stigliani S. Zedda L. Raiteri M. Bonanno G. (2002). Multiple mechanisms of transmitter release evoked by “pathologically” elevated extracellular [K+]: involvement of transporter reversal and mitochondrial calcium. J. Neurochem. 80 706–714. 10.1046/j.0022-3042.2001.00750.x 11841577
Raiteri M. Cerrito F. Cervoni A. M. Levi G. (1979). Dopamine can be released by two mechanisms differentially affected by the dopamine transport inhibitor nomifensine. J. Pharmacol. Exp. Ther. 208 195–202.216794
Rauen T. Kanner B. I. (1994). Localization of the glutamate transporter GLT-1 in rat and macaque monkey retinae. Neurosci. Lett. 169 137–140. 10.1016/0304-3940(94)90375-1 8047270
Rauen T. Wiessner M. Sullivan R. Lee A. Pow D. V. (2004). A new GLT1 splice variant: cloning and immunolocalization of GLT1c in the mammalian retina and brain. Neurochem. Int. 45 1095–1106. 10.1016/j.neuint.2004.04.006 15337309
Reyes N. Ginter C. Boudker O. (2009). Transport mechanism of a bacterial homologue of glutamate transporters. Nature 462 880–885. 10.1038/nature08616 19924125
Richerson G. B. Wu Y. (2004). Role of the GABA transporter in epilepsy. Adv. Exp. Med. Biol. 548 76–91. 10.1007/978-1-4757-6376-8_6 15250587
Rimmele T. S. Rosenberg P. A. (2016). GLT-1: the elusive presynaptic glutamate transporter. Neurochem. Int. 98 19–28. 10.1016/j.neuint.2016.04.010 27129805
Rivera C. Voipio J. Payne J. A. Ruusuvuori E. Lahtinen H. Lamsa K. (1999). The K+/Cl- co-transporter KCC2 renders GABA hyperpolarizing during neuronal maturation. Nature 397 251–255. 10.1038/16697 9930699
Roberts B. M. Doig N. M. Brimblecombe K. R. Lopes E. F. Siddorn R. E. Threlfell S. (2020). GABA uptake transporters support dopamine release in dorsal striatum with maladaptive downregulation in a parkinsonism model. Nat. Commun. 11 :4958 .
Roberts J. G. Lugo-Morales L. Z. Loziuk P. L. Sombers L. A. (2013). Real-time chemical measurements of dopamine release in the brain. Methods Mol. Biol. 964 275–294. 10.1007/978-1-62703-251-3_16 23296789
Robinson M. B. (2002). Regulated trafficking of neurotransmitter transporters: common notes but different melodies. J. Neurochem. 80 1–11. 10.1046/j.0022-3042.2001.00698.x 11796738
Rodriguez-Traver E. Solis O. Diaz-Guerra E. Ortiz O. Vergano-Vera E. Mendez-Gomez H. R. (2016). Role of Nurr1 in the generation and differentiation of dopaminergic neurons from stem cells. Neurotox Res. 30 14–31. 10.1007/s12640-015-9586-0 26678495
Roginski R. Choudhury K. Marone M. Geller H. (1993). Molecular characterization and expression of a rat-brain glutamate transporter CDNA. Anesthesiology 79 :A787 .
Romero J. de Miguel R. Ramos J. A. Fernandez-Ruiz J. J. (1998). The activation of cannabinoid receptors in striatonigral GABAergic neurons inhibited GABA uptake. Life Sci. 62 351–363. 10.1016/s0024-3205(97)01117-x 9450507
Rosenblum L. T. Trotti D. (2017). EAAT2 and the molecular signature of amyotrophic lateral sclerosis. Adv. Neurobiol. 16 117–136. 10.1007/978-3-319-55769-4_6 28828608
Rothstein J. D. Dykes-Hoberg M. Pardo C. A. Bristol L. A. Jin L. Kuncl R. W. (1996). Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 16 675–686. 10.1016/s0896-6273(00)80086-0 8785064
Rothstein J. D. Martin L. Levey A. I. Dykes-Hoberg M. Jin L. Wu D. (1994). Localization of neuronal and glial glutamate transporters. Neuron 13 713–725. 10.1016/0896-6273(94)90038-8 7917301
Rothstein J. D. Van Kammen M. Levey A. I. Martin L. J. Kuncl R. W. (1995). Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann. Neurol. 38 73–84. 10.1002/ana.410380114 7611729
Ryan R. M. Mindell J. A. (2007). The uncoupled chloride conductance of a bacterial glutamate transporter homolog. Nat. Struct. Mol. Biol. 14 365–371. 10.1038/nsmb1230 17435767
Ryan R. M. Mitrovic A. D. Vandenberg R. J. (2004). The chloride permeation pathway of a glutamate transporter and its proximity to the glutamate translocation pathway. J. Biol. Chem. 279 20742–20751. 10.1074/jbc.m304433200 14982939
Ryan R. M. Vandenberg R. J. (2016). Elevating the alternating-access model. Nat. Struct. Mol. Biol. 23 187–189. 10.1038/nsmb.3179 26931415
Sacchetti P. Brownschidle L. A. Granneman J. G. Bannon M. J. (1999). Characterization of the 5′-flanking region of the human dopamine transporter gene. Brain Res. Mol. Brain Res. 74 167–174. 10.1016/s0169-328x(99)00275-2 10640687
Sakrikar D. Mazei-Robison M. S. Mergy M. A. Richtand N. W. Han Q. Hamilton P. J. (2012). Attention deficit/hyperactivity disorder-derived coding variation in the dopamine transporter disrupts microdomain targeting and trafficking regulation. J. Neurosci. 32 5385–5397. 10.1523/jneurosci.6033-11.2012 22514303
Saksela K. Permi P. (2012). SH3 domain ligand binding: what’s the consensus and where’s the specificity? FEBS Lett. 586 2609–2614. 10.1016/j.febslet.2012.04.042 22710157
Salat K. Kulig K. (2011). GABA transporters as targets for new drugs. Future Med. Chem. 3 211–222. 10.4155/fmc.10.298 21428816
Salat K. Podkowa A. Malikowska N. Kern F. Pabel J. Wojcieszak E. (2017). Novel, highly potent and in vivo active inhibitor of GABA transporter subtype 1 with anticonvulsant, anxiolytic, antidepressant and antinociceptive properties. Neuropharmacology 113 331–342. 10.1016/j.neuropharm.2016.10.019 27771379
Salemi S. Baktash P. Rajaei B. Noori M. Amini H. Shamsara M. (2016). Efficient generation of dopaminergic-like neurons by overexpression of Nurr1 and Pitx3 in mouse induced pluripotent stem cells. Neurosci. Lett. 626 126–134. 10.1016/j.neulet.2016.05.032 27208834
Sandoval V. Riddle E. L. Ugarte Y. V. Hanson G. R. Fleckenstein A. E. (2001). Methamphetamine-induced rapid and reversible changes in dopamine transporter function: an in vitro model. J. Neurosci. 21 1413–1419. 10.1523/jneurosci.21-04-01413.2001 11160413
Saucedo-Cardenas O. Quintana-Hau J. D. Le W. D. Smidt M. P. Cox J. J. De Mayo F. (1998). Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons. Proc. Natl. Acad. Sci. U.S.A. 95 4013–4018. 10.1073/pnas.95.7.4013 9520484
Saunders C. Ferrer J. V. Shi L. Chen J. Merrill G. Lamb M. E. (2000). Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. Proc. Natl. Acad. Sci. U.S.A. 97 6850–6855. 10.1073/pnas.110035297 10823899
Schallier A. Smolders I. Van Dam D. Loyens E. De Deyn P. P. Michotte A. (2011). Region- and age-specific changes in glutamate transport in the AbetaPP23 mouse model for Alzheimer’s disease. J. Alzheimers Dis. 24 287–300. 10.3233/jad-2011-101005 21297271
Schikorski T. Stevens C. F. (1997). Quantitative ultrastructural analysis of hippocampal excitatory synapses. J. Neurosci. 17 5858–5867. 10.1523/jneurosci.17-15-05858.1997 9221783
Schitine C. S. Mendez-Flores O. G. Santos L. E. Ornelas I. Calaza K. C. Perez-Toledo K. (2015). Functional plasticity of GAT-3 in avian Muller cells is regulated by neurons via a glutamatergic input. Neurochem. Int. 82 42–51. 10.1016/j.neuint.2015.02.004 25700791
Schmitt A. Asan E. Lesch K. P. Kugler P. (2002). A splice variant of glutamate transporter GLT1/EAAT2 expressed in neurons: cloning and localization in rat nervous system. Neuroscience 109 45–61. 10.1016/s0306-4522(01)00451-1 11784699
Schmitt A. Asan E. Puschel B. Jons T. Kugler P. (1996). Expression of the glutamate transporter GLT1 in neural cells of the rat central nervous system: non-radioactive in situ hybridization and comparative immunocytochemistry. Neuroscience 71 989–1004. 10.1016/0306-4522(95)00477-7 8684627
Schmitt K. C. Rothman R. B. Reith M. E. (2013). Nonclassical pharmacology of the dopamine transporter: atypical inhibitors, allosteric modulators, and partial substrates. J. Pharmacol. Exp. Ther. 346 2–10. 10.1124/jpet.111.191056 23568856
Schoffelmeer A. N. Drukarch B. De Vries T. J. Hogenboom F. Schetters D. Pattij T. (2011). Insulin modulates cocaine-sensitive monoamine transporter function and impulsive behavior. J. Neurosci. 31 1284–1291. 10.1523/jneurosci.3779-10.2011 21273413
Schrödinger L. L. C. (2010). The PyMOL molecular graphics system. Version 1:5.
Schwartz M. D. Canales J. J. Zucchi R. Espinoza S. Sukhanov I. Gainetdinov R. R. (2018). Trace amine-associated receptor 1: a multimodal therapeutic target for neuropsychiatric diseases. Expert Opin. Ther. Targets 22 513–526. 10.1080/14728222.2018.1480723 29798691
Schwerdt H. N. Zhang E. Kim M. J. Yoshida T. Stanwicks L. Amemori S. (2018). Cellular-scale probes enable stable chronic subsecond monitoring of dopamine neurochemicals in a rodent model. Commun. Biol. 1 :144 .
Scimemi A. (2014a). Plasticity of GABA transporters: an unconventional route to shape inhibitory synaptic transmission. Front. Cell Neurosci. 8 :128 . 10.3389/fncel.2014.00128 24860430
Scimemi A. (2014b). Structure, function, and plasticity of GABA transporters. Front. Cell. Neurosci. 8 :161 . 10.3389/fncel.2014.00161 24987330
Scimemi A. Fine A. Kullmann D. M. Rusakov D. A. (2004). NR2B-containing receptors mediate cross talk among hippocampal synapses. J. Neurosci. 24 4767–4777. 10.1523/jneurosci.0364-04.2004 15152037
Scimemi A. Meabon J. S. Woltjer R. L. Sullivan J. M. Diamond J. S. Cook D. G. (2013). Amyloid-beta1-42 slows clearance of synaptically released glutamate by mislocalizing astrocytic GLT-1. J. Neurosci. 33 5312–5318. 10.1523/jneurosci.5274-12.2013 23516295
Scimemi A. Semyanov A. Sperk G. Kullmann D. M. Walker M. C. (2005). Multiple and plastic receptors mediate tonic GABA(A) receptor currents in the hippocampus. J. Neurosci. 25 10016–10024. 10.1523/jneurosci.2520-05.2005 16251450
Scimemi A. Tian H. Diamond J. S. (2009). Neuronal transporters regulate glutamate clearance, NMDA receptor activation, and synaptic plasticity in the hippocampus. J. Neurosci. 29 14581–14595. 10.1523/jneurosci.4845-09.2009 19923291
Scopelliti A. J. Font J. Vandenberg R. J. Boudker O. Ryan R. M. (2018). Structural characterisation reveals insights into substrate recognition by the glutamine transporter ASCT2/SLC1A5. Nat. Commun. 9 :38 .
Scott H. A. Gebhardt F. M. Mitrovic A. D. Vandenberg R. J. Dodd P. R. (2011). Glutamate transporter variants reduce glutamate uptake in Alzheimer’s disease. Neurobiol. Aging 32 553.e551–e511.
Seal R. P. Amara S. G. (1999). Excitatory amino acid transporters: a family in flux. Annu. Rev. Pharmacol. Toxicol. 39 431–456. 10.1146/annurev.pharmtox.39.1.431 10331091
Seal R. P. Shigeri Y. Eliasof S. Leighton B. H. Amara S. G. (2001). Sulfhydryl modification of V449C in the glutamate transporter EAAT1 abolishes substrate transport but not the substrate-gated anion conductance. Proc. Natl. Acad. Sci. U.S.A. 98 15324–15329. 10.1073/pnas.011400198 11752470
Serretti A. Mandelli L. (2008). The genetics of bipolar disorder: genome ‘hot regions,’ genes, new potential candidates and future directions. Mol. Psychiatry 13 742–771. 10.1038/mp.2008.29 18332878
Sharma A. Kazim S. F. Larson C. S. Ramakrishnan A. Gray J. D. McEwen B. S. (2019). Divergent roles of astrocytic versus neuronal EAAT2 deficiency on cognition and overlap with aging and Alzheimer’s molecular signatures. Proc. Natl. Acad. Sci. U.S.A. 116 21800–21811. 10.1073/pnas.1903566116 31591195
Sheldon A. L. Gonzalez M. I. Krizman-Genda E. N. Susarla B. T. Robinson M. B. (2008). Ubiquitination-mediated internalization and degradation of the astroglial glutamate transporter, GLT-1. Neurochem. Int. 53 296–308. 10.1016/j.neuint.2008.07.010 18805448
Shifman M. (1991). The effect of gangliosides upon recovery of aspartate/glutamatergic synapses in striatum after lesions of the rat sensorimotor cortex. Brain Res. 568 323–324. 10.1016/0006-8993(91)91419-2 1814577
Shin J. W. Nguyen K. T. Pow D. V. Knight T. Buljan V. Bennett M. R. (2009). Distribution of glutamate transporter GLAST in membranes of cultured astrocytes in the presence of glutamate transport substrates and ATP. Neurochem. Res. 34 1758–1766. 10.1007/s11064-009-9982-z 19440835
Sieber S. A. Marahiel M. A. (2005). Molecular mechanisms underlying nonribosomal peptide synthesis: approaches to new antibiotics. Chem. Rev. 105 715–738. 10.1021/cr0301191 15700962
Sims K. D. Straff D. J. Robinson M. B. (2000). Platelet-derived growth factor rapidly increases activity and cell surface expression of the EAAC1 subtype of glutamate transporter through activation of phosphatidylinositol 3-kinase. J. Biol. Chem. 275 5228–5237. 10.1074/jbc.275.7.5228 10671571
Sitcheran R. Gupta P. Fisher P. B. Baldwin A. S. (2005). Positive and negative regulation of EAAT2 by NF-kappaB: a role for N-myc in TNFalpha-controlled repression. EMBO J. 24 510–520. 10.1038/sj.emboj.7600555 15660126
Sitte H. H. Huck S. Reither H. Boehm S. Singer E. A. Pifl C. (1998). Carrier-mediated release, transport rates, and charge transfer induced by amphetamine, tyramine, and dopamine in mammalian cells transfected with the human dopamine transporter. J. Neurochem. 71 1289–1297. 10.1046/j.1471-4159.1998.71031289.x 9721755
Sogaard R. Borre L. Braunstein T. H. Madsen K. L. MacAulay N. (2013). Functional modulation of the glutamate transporter variant GLT1b by the PDZ domain protein PICK1. J. Biol. Chem. 288 20195–20207. 10.1074/jbc.m113.471128 23697999
Sonders M. S. Amara S. G. (1996). Channels in transporters. Curr. Opin. Neurobiol. 6 294–302.8794089
Sonders M. S. Zhu S. J. Zahniser N. R. Kavanaugh M. P. Amara S. G. (1997). Multiple ionic conductances of the human dopamine transporter: the actions of dopamine and psychostimulants. J. Neurosci. 17 960–974. 10.1523/jneurosci.17-03-00960.1997 8994051
Sorkina T. Doolen S. Galperin E. Zahniser N. R. Sorkin A. (2003). Oligomerization of dopamine transporters visualized in living cells by fluorescence resonance energy transfer microscopy. J. Biol. Chem. 278 28274–28283. 10.1074/jbc.m210652200 12746456
Sorkina T. Hoover B. R. Zahniser N. R. Sorkin A. (2005). Constitutive and protein kinase C-induced internalization of the dopamine transporter is mediated by a clathrin-dependent mechanism. Traffic 6 157–170. 10.1111/j.1600-0854.2005.00259.x 15634215
Stenovec M. Kreft M. Grilc S. Pangrsic T. Zorec R. (2008). EAAT2 density at the astrocyte plasma membrane and Ca(2 +)-regulated exocytosis. Mol. Membr. Biol. 25 203–215. 10.1080/09687680701790925 18428036
Stoffel W. Sasse J. Duker M. Muller R. Hofmann K. Fink T. (1996). Human high affinity, Na(+)-dependent L-glutamate/L-aspartate transporter GLAST-1 (EAAT-1): gene structure and localization to chromosome 5p11-p12. FEBS Lett. 386 189–193. 10.1016/0014-5793(96)00424-3 8647279
Su Z. Z. Leszczyniecka M. Kang D. C. Sarkar D. Chao W. Volsky D. J. (2003). Insights into glutamate transport regulation in human astrocytes: cloning of the promoter for excitatory amino acid transporter 2 (EAAT2). Proc. Natl. Acad. Sci. U.S.A. 100 1955–1960. 10.1073/pnas.0136555100 12578975
Sullivan R. Rauen T. Fischer F. Wiessner M. Grewer C. Bicho A. (2004). Cloning, transport properties, and differential localization of two splice variants of GLT-1 in the rat CNS: implications for CNS glutamate homeostasis. Glia 45 155–169. 10.1002/glia.10317 14730709
Sulzer D. Chen T. K. Lau Y. Y. Kristensen H. Rayport S. Ewing A. (1995). Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J. Neurosci. 15 4102–4108. 10.1523/jneurosci.15-05-04102.1995 7751968
Sulzer D. Maidment N. T. Rayport S. (1993). Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons. J. Neurochem. 60 527–535. 10.1111/j.1471-4159.1993.tb03181.x 8419534
Susarla B. T. Robinson M. B. (2003). Rottlerin, an inhibitor of protein kinase Cdelta (PKCdelta), inhibits astrocytic glutamate transport activity and reduces GLAST immunoreactivity by a mechanism that appears to be PKCdelta-independent. J. Neurochem. 86 635–645. 10.1046/j.1471-4159.2003.01886.x 12859677
Susarla B. T. Robinson M. B. (2008). Internalization and degradation of the glutamate transporter GLT-1 in response to phorbol ester. Neurochem. Int. 52 709–722. 10.1016/j.neuint.2007.08.020 17919781
Susarla B. T. Seal R. P. Zelenaia O. Watson D. J. Wolfe J. H. Amara S. G. (2004). Differential regulation of GLAST immunoreactivity and activity by protein kinase C: evidence for modification of amino and carboxyl termini. J. Neurochem. 91 1151–1163. 10.1111/j.1471-4159.2004.02791.x 15569258
Swanson R. A. Liu J. Miller J. W. Rothstein J. D. Farrell K. Stein B. A. (1997). Neuronal regulation of glutamate transporter subtype expression in astrocytes. J. Neurosci. 17 932–940. 10.1523/jneurosci.17-03-00932.1997 8994048
Sylantyev S. Savtchenko L. P. O’Neill N. Rusakov D. A. (2020). Extracellular GABA waves regulate coincidence detection in excitatory circuits. J. Physiol. 598 4047–4062. 10.1113/jp279744 32667048
Tai Y. H. Wang Y. H. Tsai R. Y. Wang J. J. Tao P. L. Liu T. M. (2007). Amitriptyline preserves morphine’s antinociceptive effect by regulating the glutamate transporter GLAST and GLT-1 trafficking and excitatory amino acids concentration in morphine-tolerant rats. Pain 129 343–354. 10.1016/j.pain.2007.01.031 17346885
Tan J. Zelenaia O. Correale D. Rothstein J. D. Robinson M. B. (1999). Expression of the GLT-1 subtype of Na+-dependent glutamate transporter: pharmacological characterization and lack of regulation by protein kinase C. J. Pharmacol. Exp. Ther. 289 1600–1610.10336558
Tanaka K. (1993). Cloning and expression of a glutamate transporter from mouse brain. Neurosci. Lett. 159 183–186. 10.1016/0304-3940(93)90829-a 7903437
Tebano M. T. Martire A. Potenza R. L. Gro C. Pepponi R. Armida M. (2008). Adenosine A(2A) receptors are required for normal BDNF levels and BDNF-induced potentiation of synaptic transmission in the mouse hippocampus. J. Neurochem. 104 279–286.18005343
Tian Y. Kapatos G. Granneman J. G. Bannon M. J. (1994). Dopamine and gamma-aminobutyric acid transporters: differential regulation by agents that promote phosphorylation. Neurosci. Lett. 173 143–146. 10.1016/0304-3940(94)90169-4 7936402
Todorov A. A. Kolchev C. B. Todorov A. B. (2005). Tiagabine and gabapentin for the management of chronic pain. Clin. J. Pain 21 358–361. 10.1097/01.ajp.0000110637.14355.77 15951655
Tonsfeldt K. J. Suchland K. L. Beeson K. A. Lowe J. D. Li M. H. Ingram S. L. (2016). Sex Differences in GABAA signaling in the periaqueductal gray induced by persistent inflammation. J. Neurosci. 36 1669–1681. 10.1523/jneurosci.1928-15.2016 26843648
Torp R. Danbolt N. C. Babaie E. Bjoras M. Seeberg E. Storm-Mathisen J. (1994). Differential expression of two glial glutamate transporters in the rat brain: an in situ hybridization study. Eur. J. Neurosci. 6 936–942. 10.1111/j.1460-9568.1994.tb00587.x 7952280
Torp R. Hoover F. Danbolt N. C. Storm-Mathisen J. Ottersen O. P. (1997). Differential distribution of the glutamate transporters GLT1 and rEAAC1 in rat cerebral cortex and thalamus: an in situ hybridization analysis. Anat. Embryol. 195 317–326. 10.1007/s004290050051 9108197
Torres G. E. Gainetdinov R. R. Caron M. G. (2003). Plasma membrane monoamine transporters: structure, regulation and function. Nat. Rev. Neurosci. 4 13–25. 10.1038/nrn1008 12511858
Torres G. E. Yao W. D. Mohn A. R. Quan H. Kim K. M. Levey A. I. (2001). Functional interaction between monoamine plasma membrane transporters and the synaptic PDZ domain-containing protein PICK1. Neuron 30 121–134. 10.1016/s0896-6273(01)00267-7 11343649
Torres-Salazar D. Fahlke C. (2007). Neuronal glutamate transporters vary in substrate transport rate but not in unitary anion channel conductance. J. Biol. Chem. 282 34719–34726. 10.1074/jbc.m704118200 17908688
Trotti D. Peng J. B. Dunlop J. Hediger M. A. (2001). Inhibition of the glutamate transporter EAAC1 expressed in Xenopus oocytes by phorbol esters. Brain Res. 914 196–203. 10.1016/s0006-8993(01)02802-5 11578612
Trotti D. Volterra A. Lehre K. P. Rossi D. Gjesdal O. Racagni G. (1995). Arachidonic acid inhibits a purified and reconstituted glutamate transporter directly from the water phase and not via the phospholipid membrane. J. Biol. Chem. 270 9890–9895. 10.1074/jbc.270.17.9890 7730372
Tzingounis A. V. Wadiche J. I. (2007). Glutamate transporters: confining runaway excitation by shaping synaptic transmission. Nat. Rev. Neurosci. 8 935–947. 10.1038/nrn2274 17987031
Underhill S. M. Ingram S. L. Ahmari S. E. Veenstra-VanderWeele J. Amara S. G. (2019). Neuronal excitatory amino acid transporter EAAT3: emerging functions in health and disease. Neurochem. Int. 123 69–76. 10.1016/j.neuint.2018.05.012 29800605
Underhill S. M. Wheeler D. S. Amara S. G. (2015). Differential regulation of two isoforms of the glial glutamate transporter EAAT2 by DLG1 and CaMKII. J. Neurosci. 35 5260–5270. 10.1523/jneurosci.4365-14.2015 25834051
Underhill S. M. Wheeler D. S. Li M. Watts S. D. Ingram S. L. Amara S. G. (2014). Amphetamine modulates excitatory neurotransmission through endocytosis of the glutamate transporter EAAT3 in dopamine neurons. Neuron 83 404–416. 10.1016/j.neuron.2014.05.043 25033183
Untiet V. Kovermann P. Gerkau N. J. Gensch T. Rose C. R. Fahlke C. (2017). Glutamate transporter-associated anion channels adjust intracellular chloride concentrations during glial maturation. Glia 65 388–400. 10.1002/glia.23098 27859594
Vandenbergh D. J. Persico A. M. Hawkins A. L. Griffin C. A. Li X. Jabs E. W. (1992a). Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics 14 1104–1106. 10.1016/s0888-7543(05)80138-7 1478653
Vandenbergh D. J. Persico A. M. Uhl G. R. (1992b). A human dopamine transporter cDNA predicts reduced glycosylation, displays a novel repetitive element and provides racially-dimorphic TaqI RFLPs. Brain Res. Mol. Brain Res. 15 161–166. 10.1016/0169-328x(92)90165-8 1359373
Vaughan R. A. Huff R. A. Uhl G. R. Kuhar M. J. (1997). Protein kinase C-mediated phosphorylation and functional regulation of dopamine transporters in striatal synaptosomes. J. Biol. Chem. 272 15541–15546. 10.1074/jbc.272.24.15541 9182590
Vaz S. H. Cristovao-Ferreira S. Ribeiro J. A. Sebastiao A. M. (2008). Brain-derived neurotrophic factor inhibits GABA uptake by the rat hippocampal nerve terminals. Brain Res. 1219 19–25. 10.1016/j.brainres.2008.04.008 18539266
Vaz S. H. Jorgensen T. N. Cristovao-Ferreira S. Duflot S. Ribeiro J. A. Gether U. (2011). Brain-derived neurotrophic factor (BDNF) enhances GABA transport by modulating the trafficking of GABA transporter-1 (GAT-1) from the plasma membrane of rat cortical astrocytes. J. Biol. Chem. 286 40464–40476. 10.1074/jbc.m111.232009 21969376
Venderova K. Brown T. M. Brotchie J. M. (2005). Differential effects of endocannabinoids on [(3)H]-GABA uptake in the rat Globus pallidus. Exp. Neurol. 194 284–287. 10.1016/j.expneurol.2005.02.012 15899265
Ventura R. Harris K. M. (1999). Three-dimensional relationships between hippocampal synapses and astrocytes. J. Neurosci. 19 6897–6906. 10.1523/jneurosci.19-16-06897.1999 10436047
Verdon G. Boudker O. (2012). Crystal structure of an asymmetric trimer of a bacterial glutamate transporter homolog. Nat. Struct. Mol. Biol. 19 355–357. 10.1038/nsmb.2233 22343718
Veruki M. L. Morkve S. H. Hartveit E. (2006). Activation of a presynaptic glutamate transporter regulates synaptic transmission through electrical signaling. Nat. Neurosci. 9 1388–1396. 10.1038/nn1793 17041592
Vina-Vilaseca A. Sorkin A. (2010). Lysine 63-linked polyubiquitination of the dopamine transporter requires WW3 and WW4 domains of Nedd4-2 and UBE2D ubiquitin-conjugating enzymes. J. Biol. Chem. 285 7645–7656. 10.1074/jbc.m109.058990 20051513
Voisin P. Viratelle O. Girault J. M. Morrison-Bogorad M. Labouesse J. (1993). Plasticity of astroglial glutamate and γ-Aminobutyric acid uptake in cell cultures derived from postnatal mouse cerebellum. J. Neurochem. 60 114–127. 10.1111/j.1471-4159.1993.tb05829.x 8093258
Volterra A. Trotti D. Cassutti P. Tromba C. Galimberti R. Lecchi P. (1992). A role for the arachidonic acid cascade in fast synaptic modulation: ion channels and transmitter uptake systems as target proteins. Adv. Exp. Med. Biol. 318 147–158. 10.1007/978-1-4615-3426-6_13 1378992
Volterra A. Trotti D. Racagni G. (1994a). Glutamate uptake is inhibited by arachidonic acid and oxygen radicals via two distinct and additive mechanisms. Mol. Pharmacol. 46 986–992.7969090
Volterra A. Trotti D. Tromba C. Floridi S. Racagni G. (1994b). Glutamate uptake inhibition by oxygen free radicals in rat cortical astrocytes. J. Neurosci. 14 2924–2932. 10.1523/jneurosci.14-05-02924.1994 7910203
Voutsinos B. Dutuit M. Reboul A. Fevre-Montange M. Bernard A. Trouillas P. (1998). Serotoninergic control of the activity and expression of glial GABA transporters in the rat cerebellum. Glia 23 45–60. 10.1002/(sici)1098-1136(199805)23:1<45::aid-glia5>3.0.co;2-3 9562184
Wadiche J. I. Amara S. G. Kavanaugh M. P. (1995a). Ion fluxes associated with excitatory amino acid transport. Neuron 15 721–728. 10.1016/0896-6273(95)90159-0 7546750
Wadiche J. I. Arriza J. L. Amara S. G. Kavanaugh M. P. (1995b). Kinetics of a human glutamate transporter. Neuron 14 1019–1027. 10.1016/0896-6273(95)90340-2 7748550
Wadiche J. I. Jahr C. E. (2005). Patterned expression of Purkinje cell glutamate transporters controls synaptic plasticity. Nat. Neurosci. 8 1329–1334. 10.1038/nn1539 16136036
Wadiche J. I. Kavanaugh M. P. (1998). Macroscopic and microscopic properties of a cloned glutamate transporter/chloride channel. J. Neurosci. 18 7650–7661. 10.1523/jneurosci.18-19-07650.1998 9742136
Walker M. C. van der Donk W. A. (2016). The many roles of glutamate in metabolism. J. Ind. Microbiol. Biotechnol. 43 419–430. 10.1007/s10295-015-1665-y 26323613
Wang D. Deken S. L. Whitworth T. L. Quick M. W. (2003). Syntaxin 1A inhibits GABA flux, efflux, and exchange mediated by the rat brain GABA transporter GAT1. Mol. Pharmacol. 64 905–913. 10.1124/mol.64.4.905 14500747
Wang Z. Li W. Mitchell C. K. Carter-Dawson L. (2003). Activation of protein kinase C reduces GLAST in the plasma membrane of rat Muller cells in primary culture. Vis. Neurosci. 20 611–619. 10.1017/s0952523803206039 15088714
Wang D. Quick M. W. (2005). Trafficking of the plasma membrane gamma-aminobutyric acid transporter GAT1. Size and rates of an acutely recycling pool. J. Biol. Chem. 280 18703–18709. 10.1074/jbc.m500381200 15778221
Wang J. Michelhaugh S. K. Bannon M. J. (2007). Valproate robustly increases Sp transcription factor-mediated expression of the dopamine transporter gene within dopamine cells. Eur. J. Neurosci. 25 1982–1986. 10.1111/j.1460-9568.2007.05460.x 17439486
Wang K. H. Penmatsa A. Gouaux E. (2015). Neurotransmitter and psychostimulant recognition by the dopamine transporter. Nature 521 322–327. 10.1038/nature14431 25970245
Wang X. Boudker O. (2020). Large domain movements through the lipid bilayer mediate substrate release and inhibition of glutamate transporters. eLife 9 :e58417 .
Wang Y. Lu S. Qu Z. Wu L. Wang Y. (2017). Sonic hedgehog induces GLT-1 degradation via PKC delta to suppress its transporter activities. Neuroscience 365 217–225. 10.1016/j.neuroscience.2017.09.051 28993237
Watzke N. Bamberg E. Grewer C. (2001). Early intermediates in the transport cycle of the neuronal excitatory amino acid carrier EAAC1. J. Gen. Physiol. 117 547–562. 10.1085/jgp.117.6.547 11382805
Watzke N. Grewer C. (2001). The anion conductance of the glutamate transporter EAAC1 depends on the direction of glutamate transport. FEBS Lett. 503 121–125. 10.1016/s0014-5793(01)02715-6 11513867
Wenzel J. Lammert G. Meyer U. Krug M. (1991). The influence of long-term potentiation on the spatial relationship between astrocyte processes and potentiated synapses in the dentate gyrus neuropil of rat brain. Brain Res. 560 122–131. 10.1016/0006-8993(91)91222-m 1760721
Wheeler D. S. Ebben A. L. Kurtoglu B. Lovell M. E. Bohn A. T. Jasek I. A. (2017). Corticosterone regulates both naturally occurring and cocaine-induced dopamine signaling by selectively decreasing dopamine uptake. Eur. J. Neurosci. 46 2638–2646. 10.1111/ejn.13730 28965353
Wheeler D. S. Underhill S. M. Stolz D. B. Murdoch G. H. Thiels E. Romero G. (2015). Amphetamine activates Rho GTPase signaling to mediate dopamine transporter internalization and acute behavioral effects of amphetamine. Proc. Natl. Acad. Sci. U.S.A. 112 E7138–E7147.26553986
Whitworth T. L. Quick M. W. (2001). Upregulation of gamma-aminobutyric acid transporter expression: role of alkylated gamma-aminobutyric acid derivatives. Biochem. Soc. Trans. 29 736–741. 10.1042/bst0290736 11709066
Wieczorek W. J. Kruk Z. L. (1994). Differential action of (+)-amphetamine on electrically evoked dopamine overflow in rat brain slices containing corpus striatum and nucleus accumbens. Br. J. Pharmacol. 111 829–836. 10.1111/j.1476-5381.1994.tb14813.x 8019759
Williams J. M. Owens W. A. Turner G. H. Saunders C. Dipace C. Blakely R. D. (2007). Hypoinsulinemia regulates amphetamine-induced reverse transport of dopamine. PLoS Biol. 5 :e274 . 10.1371/journal.pbio.0050274 17941718
Wilson J. M. Khabazian I. Pow D. V. Craig U. K. Shaw C. A. (2003). Decrease in glial glutamate transporter variants and excitatory amino acid receptor down-regulation in a murine model of ALS-PDC. Neuromolecul. Med. 3 105–118. 10.1385/nmm:3:2:105
Winter N. Kovermann P. Fahlke C. (2012). A point mutation associated with episodic ataxia 6 increases glutamate transporter anion currents. Brain 135 3416–3425. 10.1093/brain/aws255 23107647
Witcher M. R. Kirov S. A. Harris K. M. (2007). Plasticity of perisynaptic astroglia during synaptogenesis in the mature rat hippocampus. Glia 55 13–23. 10.1002/glia.20415 17001633
Witcher M. R. Park Y. D. Lee M. R. Sharma S. Harris K. M. Kirov S. A. (2010). Three-dimensional relationships between perisynaptic astroglia and human hippocampal synapses. Glia 58 572–587.19908288
Woo T. U. Whitehead R. E. Melchitzky D. S. Lewis D. A. (1998). A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 95 5341–5346. 10.1073/pnas.95.9.5341 9560277
Wu X. Kihara T. Akaike A. Niidome T. Sugimoto H. (2010). PI3K/Akt/mTOR signaling regulates glutamate transporter 1 in astrocytes. Biochem. Biophys. Res. Commun. 393 514–518. 10.1016/j.bbrc.2010.02.038 20152809
Wu Y. Wang W. Diez-Sampedro A. Richerson G. B. (2007). Nonvesicular inhibitory neurotransmission via reversal of the GABA transporter GAT-1. Neuron 56 851–865. 10.1016/j.neuron.2007.10.021 18054861
Wu Y. Wang W. Richerson G. B. (2003). Vigabatrin induces tonic inhibition via GABA transporter reversal without increasing vesicular GABA release. J. Neurophysiol. 89 2021–2034. 10.1152/jn.00856.2002 12612025
Xie Y. Y. Qu J. Zhou L. Lv N. Gong J. E. Cao Y. Z. (2017). Lack of association between SLC6A11 genetic polymorphisms and drug resistant epilepsy in chinese han population. Clin. Lab. 63 1113–1120.28792706
Xu Y. F. Cai Y. Q. Cai G. Q. Jiang J. Sheng Z. J. Wang Z. G. (2008). Hypoalgesia in mice lacking GABA transporter subtype 1. J. Neurosci. Res. 86 465–470. 10.1002/jnr.21499 17918738
Yamashita A. Singh S. K. Kawate T. Jin Y. Gouaux E. (2005). Crystal structure of a bacterial homologue of Na+/Cl–dependent neurotransmitter transporters. Nature 437 215–223. 10.1038/nature03978 16041361
Yan X. Yadav R. Gao M. Weng H. R. (2014). Interleukin-1 beta enhances endocytosis of glial glutamate transporters in the spinal dorsal horn through activating protein kinase C. Glia 62 1093–1109. 10.1002/glia.22665 24677092
Yan X. X. Cariaga W. A. Ribak C. E. (1997). Immunoreactivity for GABA plasma membrane transporter, GAT-1, in the developing rat cerebral cortex: transient presence in the somata of neocortical and hippocampal neurons. Brain Res. Dev. Brain Res. 99 1–19. 10.1016/s0165-3806(96)00192-7 9088561
Yan X. X. Ribak C. E. (1998). Developmental expression of gamma-aminobutyric acid transporters (GAT-1 and GAT-3) in the rat cerebellum: evidence for a transient presence of GAT-1 in Purkinje cells. Brain Res. Dev. Brain Res. 111 253–269. 10.1016/s0165-3806(98)00144-8 9838150
Yang Y. Kinney G. A. Spain W. J. Breitner J. C. Cook D. G. (2004). Presenilin-1 and intracellular calcium stores regulate neuronal glutamate uptake. J. Neurochem. 88 1361–1372. 10.1046/j.1471-4159.2003.02279.x 15009636
Yernool D. Boudker O. Jin Y. Gouaux E. (2004). Structure of a glutamate transporter homologue from Pyrococcus horikoshii. Nature 431 811–818. 10.1038/nature03018 15483603
Yoo S. Y. Kim J. H. Do S. H. Zuo Z. (2008). Inhibition of the activity of excitatory amino acid transporter 4 expressed in Xenopus oocytes after chronic exposure to ethanol. Alcohol. Clin. Exp. Res. 32 1292–1298. 10.1111/j.1530-0277.2008.00697.x 18540911
Yu X. Plotnikova O. Bonin P. D. Subashi T. A. McLellan T. J. Dumlao D. (2019). Cryo-EM structures of the human glutamine transporter SLC1A5 (ASCT2) in the outward-facing conformation. eLife 8 :e48120 .
Zeigerer A. McBrayer M. K. McGraw T. E. (2004). Insulin stimulation of GLUT4 exocytosis, but not its inhibition of endocytosis, is dependent on RabGAP AS160. Mol. Biol. Cell 15 4406–4415. 10.1091/mbc.e04-04-0333 15254270
Zelenaia O. Schlag B. D. Gochenauer G. E. Ganel R. Song W. Beesley J. S. (2000). Epidermal growth factor receptor agonists increase expression of glutamate transporter GLT-1 in astrocytes through pathways dependent on phosphatidylinositol 3-kinase and transcription factor NF-kappaB. Mol. Pharmacol. 57 667–678. 10.1124/mol.57.4.667 10727511
Zerangue N. Arriza J. L. Amara S. G. Kavanaugh M. P. (1995). Differential modulation of human glutamate transporter subtypes by Arachidonic acid. J. Biol. Chem. 270 6433–6435. 10.1074/jbc.270.12.6433 7896776
Zerangue N. Kavanaugh M. P. (1996). Flux coupling in a neuronal glutamate transporter. Nature 383 634–637. 10.1038/383634a0 8857541
Zestos A. G. Mikelman S. R. Kennedy R. T. Gnegy M. E. (2016). PKCbeta inhibitors attenuate amphetamine-stimulated dopamine efflux. ACS Chem. Neurosci. 7 757–766. 10.1021/acschemneuro.6b00028 26996926
Zetterstrom R. H. Solomin L. Jansson L. Hoffer B. J. Olson L. Perlmann T. (1997). Dopamine neuron agenesis in Nurr1-deficient mice. Science 276 248–250. 10.1126/science.276.5310.248 9092472
Zhang H. Li S. Wang M. Vukusic B. Pristupa Z. B. Liu F. (2009). Regulation of dopamine transporter activity by carboxypeptidase E. Mol. Brain 2 :10 . 10.1186/1756-6606-2-10 19419578
Zhang L. Coffey L. L. Reith M. E. (1997). Regulation of the functional activity of the human dopamine transporter by protein kinase C. Biochem. Pharmacol. 53 677–688. 10.1016/s0006-2952(96)00898-2 9113087
Zhang L. Li L. Wang B. Qian D. M. Song X. X. Hu M. (2014). HCMV induces dysregulation of glutamate uptake and transporter expression in human fetal astrocytes. Neurochem. Res. 39 2407–2418. 10.1007/s11064-014-1445-5 25293581
Zhang Q. Fukuda M. Van Bockstaele E. Pascual O. Haydon P. G. (2004). Synaptotagmin IV regulates glial glutamate release. Proc. Natl. Acad. Sci. U.S.A. 101 9441–9446. 10.1073/pnas.0401960101 15197251
Zhou J. Sutherland M. L. (2004). Glutamate transporter cluster formation in astrocytic processes regulates glutamate uptake activity. J. Neurosci. 24 6301–6306. 10.1523/jneurosci.1404-04.2004 15254085
Zhu S. J. Kavanaugh M. P. Sonders M. S. Amara S. G. Zahniser N. R. (1997). Activation of protein kinase C inhibits uptake, currents and binding associated with the human dopamine transporter expressed in Xenopus oocytes. J. Pharmacol. Exp. Ther. 282 1358–1365.9316847
Zike I. D. Chohan M. O. Kopelman J. M. Krasnow E. N. Flicker D. Nautiyal K. M. (2017). OCD candidate gene SLC1A1/EAAT3 impacts basal ganglia-mediated activity and stereotypic behavior. Proc. Natl. Acad. Sci. U.S.A. 114 5719–5724. 10.1073/pnas.1701736114 28507136
Zschocke J. Bayatti N. Clement A. M. Witan H. Figiel M. Engele J. (2005). Differential promotion of glutamate transporter expression and function by glucocorticoids in astrocytes from various brain regions. J. Biol. Chem. 280 34924–34932. 10.1074/jbc.m502581200 16079146

